# EDGAR Filing Document

**Accession Number:** 0001836564
**File Stem:** 0001628280-25-039789
**Filing Date:** 2025-8
**Character Count:** 175754
**Document Hash:** 5c871261f0efe05673feea11902dfe13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-039789.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001628280-25-039789

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 96

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Valneva SE
- **CENTRAL INDEX KEY:** 0001836564
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40377
- **FILM NUMBER:** 251204687

**BUSINESS ADDRESS:**
- **STREET 1:** 6, RUE ALAIN BOMBARD
- **CITY:** SAINT-HERBLAIN
- **STATE:** I0
- **ZIP:** 44800
- **BUSINESS PHONE:** 33 2 28 07 37 10

**MAIL ADDRESS:**
- **STREET 1:** 6, RUE ALAIN BOMBARD
- **CITY:** SAINT-HERBLAIN
- **STATE:** I0
- **ZIP:** 44800

?xml version='1.0' encoding='ASCII'? valn-20250630

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: August 12, 2025**

Commission File Number: **001-40377**

**Valneva SE**

**(Exact name of Registrant as specified in its charter and translation of Registrant's name into English)**

**France**

(Jurisdiction of incorporation or organization)

**6 rue Alain Bombard**

**44800 Saint-Herblain, France**

(Address of principal executive offices)

**Thomas Lingelbach**

**Chief Executive Officer, Valneva SE**

**6 rue Alain Bombard**

**44800 Saint-Herblain, France**

**Tel: +33 2 28 07 37 10**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

On August 12, 2025, the Registrant announced its results from the six months ended June 30, 2025 including the report and unaudited interim condensed consolidated financial statements included in this Form 6-K. Additionally, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Form 6-K, but excluding the section entitled "Financial Outlook" in Exhibit 99.1, is hereby incorporated by reference into the registrant's Registration Statement on Form F-3 (File No. 333-286071).

---

| | |
|:---|:---|
| **<u>Exhibits</u>** | |
| &nbsp;&nbsp;Exhibit 99.1 | &nbsp;&nbsp;<u>[Press Release dated August 12, 2025](h1_resultsxprxfinalxdraft.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| | **<u>Valneva SE</u>** (Registrant) |
| Date: August 12, 2025 |  |
| | Thomas Lingelbach |
| | Chief Executive Officer and President |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| GENERAL INTRODUCTORY COMMENTS AND DISCLAIMER | <u>[3](#ib099df8785cf471897ebf401a554ef4d_13)</u> |
| I. MANAGEMENT REPORT | <u>[4](#ib099df8785cf471897ebf401a554ef4d_16)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;1 Overview | <u>[4](#ib099df8785cf471897ebf401a554ef4d_19)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;2 Operational Review | <u>[4](#ib099df8785cf471897ebf401a554ef4d_22)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;3 Financial Review | <u>[10](#ib099df8785cf471897ebf401a554ef4d_25)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;4 Operational and Strategic Outlook 2025 | <u>[12](#ib099df8785cf471897ebf401a554ef4d_28)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;5 Risk Factors | <u>[13](#ib099df8785cf471897ebf401a554ef4d_31)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;6 Related Parties' Transactions | <u>[15](#ib099df8785cf471897ebf401a554ef4d_34)</u> |
| II. STATUTORY AUDITORS' REVIEW REPORT ON THE HALF YEAR FINANCIAL INFORMATION (PERIOD FROM JANUARY 1 TO JUNE 30, 2025) | <u>[1](#ib099df8785cf471897ebf401a554ef4d_37)</u> |
| III. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS <br>AS AT JUNE 30, 2025  | <u>[16](#ib099df8785cf471897ebf401a554ef4d_43)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;1 Unaudited Interim Consolidated Statement of Profit or Loss and Comprehensive Income | <u>[16](#ib099df8785cf471897ebf401a554ef4d_43)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;2 Unaudited Interim Condensed Consolidated Statement of Financial Position | <u>[17](#ib099df8785cf471897ebf401a554ef4d_46)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;3 Unaudited Interim Condensed Consolidated Statement of Cash Flows | <u>[18](#ib099df8785cf471897ebf401a554ef4d_49)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;4 Unaudited Interim Condensed Consolidated Statement of Changes in Equity | <u>[19](#ib099df8785cf471897ebf401a554ef4d_52)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;5 Selected Notes to the Unaudited Interim Condensed Consolidated Financial Statements | <u>[20](#ib099df8785cf471897ebf401a554ef4d_55)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 General information | <u>[20](#ib099df8785cf471897ebf401a554ef4d_58)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 Summary of significant accounting policies | <u>[22](#ib099df8785cf471897ebf401a554ef4d_61)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 Critical accounting judgements and key sources of estimation uncertainty | <u>[23](#ib099df8785cf471897ebf401a554ef4d_85)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 Segment information | <u>[23](#ib099df8785cf471897ebf401a554ef4d_97)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 Revenues | <u>[23](#ib099df8785cf471897ebf401a554ef4d_103)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 Expenses by nature | <u>[25](#ib099df8785cf471897ebf401a554ef4d_124)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7 Other income/(expenses), net | <u>[26](#ib099df8785cf471897ebf401a554ef4d_136)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8 Finance income/(expenses), net | <u>[27](#ib099df8785cf471897ebf401a554ef4d_145)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9 Impairment testing | <u>[27](#ib099df8785cf471897ebf401a554ef4d_175)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10 Inventories | <u>[27](#ib099df8785cf471897ebf401a554ef4d_196)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11 Trade receivables | <u>[28](#ib099df8785cf471897ebf401a554ef4d_199)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13 Cash and cash equivalents | <u>[29](#ib099df8785cf471897ebf401a554ef4d_205)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.14 Borrowings | <u>[29](#ib099df8785cf471897ebf401a554ef4d_238)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.15 Trade payables and accruals | <u>[31](#ib099df8785cf471897ebf401a554ef4d_250)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.16 Contract liabilities | <u>[31](#ib099df8785cf471897ebf401a554ef4d_262)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.17 Refund liabilities | <u>[31](#ib099df8785cf471897ebf401a554ef4d_262)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.18 Cash flow information | <u>[33](#ib099df8785cf471897ebf401a554ef4d_283)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.20 Related-party transactions | <u>[34](#ib099df8785cf471897ebf401a554ef4d_301)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.21 Events after the reporting period | <u>[34](#ib099df8785cf471897ebf401a554ef4d_310)</u> |
| IV. RESPONSIBILITY STATEMENT | <u>[1](#ib099df8785cf471897ebf401a554ef4d_313)</u> |

---

---

| | |
|:---|:---|
| 2 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

GENERAL INTRODUCTORY COMMENTS AND DISCLAIMER

In this interim financial report, unless stated otherwise, the terms "Company", "Valneva" and "Group" refer to Valneva SE and its subsidiaries.

"Valneva," the Valneva logo, "IXIARO," "JESPECT," "DUKORAL", "IXCHIQ" and other trademarks or service marks of Valneva SE of any of its business partners appearing in this Half-Year Financial Report are the property of Valneva, its subsidiaries or its business partners, as applicable. Solely for convenience, the trademarks, service marks and trade names referred to in this Half-Year Financial Report are listed without the® and™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All other trademarks, trade names and service marks appearing in this Half-Year Financial Report are the property of their respective owners. Valneva does not intend to use or display other companies' trademarks and trade names to imply any relationship with, or endorsement or sponsorship of Valneva by, any other companies.

This interim financial report contains forward-looking statements about the Company's targets and forecasts, especially in chapter "I.4 Operational and Strategic Outlook 2025". Such statements are based on data, assumptions and estimates that the Company considers reasonable.

All forward-looking statements in this interim financial report are subject to change or adjustments as a result of uncertainties inherent in all research and development activities, as well as the economic, financial, competitive and regulatory environment. In addition, the Company's business activities and its ability to meet its targets and forecasts may be affected if some of the risk factors described in chapter "I.5 Risk Factors" of this interim financial report, or any unexpected developments, arise.

Investors are urged to pay careful attention to the risk factors set forth in chapter "I.5 Risk Factors" of this interim

report before making any investment decision. The risks presented in this interim report are those the Company considers to be the most significant for the second half of 2025 and are not all of the risks that the Company faces during this period or beyond. One or more of these risks may have an adverse effect on the Company's activities, condition, the results of its operations or its targets and forecasts. Furthermore, other risks not yet identified or considered as significant by the Company could have the same adverse effects, and investors may lose all or part of their investment.

Forward-looking statements, targets and forecasts shown in this interim financial report may be affected by risks, either known or unknown uncertainties and other factors that may lead to the Company's future results of operations, performance and achievements differing significantly from the stated or implied targets and forecasts. These factors may include changes in economic or trading conditions and regulations, as well as the factors set forth in chapter "I.5 Risk Factors" of this interim report as well as those risks and uncertainties discussed or identified in Valneva's public filings with the "Autorité des Marchés Financiers" (AMF) in France, including those listed in the Company's 2024 Universal Registration Document filed with the AMF on March 25, 2025, which is available on the websites of the Company and the AMF, and public filings and reports filed with the U.S. Securities and Exchange Commission (SEC), including the Company's 2024 annual report on Form 20-F available on the SEC's website.

References to Valneva's website and social media accounts are included for information only and the content contained therein, or that can be accessed through, Valneva's website and these social media accounts is not incorporated by reference into this report and does not constitute a part of this report.

![VAL_Logo_4c.jpg](valn-20250630_g1.jpg)<sub>3</sub>

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

I. MANAGEMENT REPORT

1 Overview

Valneva is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The Company takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

The Company has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines.

Revenues from Valneva's growing commercial business help fuel the continued advancement of its vaccine

development pipeline. This includes the only Lyme disease vaccine candidate (VLA15) in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced tetravalent Shigella vaccine candidate as well as vaccine candidates against the Zika virus and other global public health threats.

Valneva has around 700 employees across its operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S.

Our commercialized products and advanced clinical pipeline are summarized below:

![R&D Portfolio.jpg](valn-20250630_g2.jpg)

2 Operational Review

2.1 Vaccine Research & Development (R&D)

Valneva's pipeline is composed of differentiated vaccine candidates at various stages of research and development. The Company aims to develop vaccine candidates that are either first-, best- or only-in-class and address unmet needs in infectious diseases.

Each of these assets either target diseases currently lacking a preventative or effective therapeutic treatment option or may have meaningful advantages compared to existing vaccine solutions or treatment options.

Valneva develops products towards marketing approval and commercialization either in-house, as illustrated by its chikungunya vaccine, or through strategic licensing or partnering, as illustrated by its collaborations with Pfizer

for its Lyme disease vaccine candidate VLA15 and with LimmaTech Biologics for its Shigella vaccine candidate.

Lyme Disease Vaccine Candidate – VLA15

*Overview of Lyme Disease*

Lyme disease is a systemic infection caused by Borrelia burgdorferi bacteria transmitted to humans by infected Ixodes ticks<sup>1</sup>. It is considered the most common vector-borne illness in the Northern Hemisphere<sup>2</sup>.

While the true incidence of Lyme disease is unknown, it is estimated to annually affect approximately 476,000 people in the United States and 130,000 people in Europe<sup>3,4</sup>. Research suggests that Lyme disease cases may rise 92% by 2100 in the U.S. due to climate change<sup>5</sup>. Although most patients recover from Lyme disease, 10-20% have persistent symptoms, which for some are chronic and disabling. Studies indicate that Lyme disease costs up to approximately $1.3 billion each year in direct medical costs in the U.S. alone<sup>6</sup>.

<sup>1</sup> *Stanek et al. 2012, The Lancet 379:461–473*

<sup>2</sup> *Gern L, Falco RC. Lyme disease. Rev Sci Tech. 2000 Apr;19(1):121-35*

<sup>3</sup> *Burn L, et al. Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005–2020). April 2023. Vector Borne and Zoonotic Diseases. 23(4): 156–171.* 

<sup>4</sup> *Kugeler KJ, et al. Estimating the frequency of Lyme disease diagnoses—United States, 2010-2018. February 2021. Emergency Infectious Disease. 27(2).* 

<sup>5</sup> *Lyme disease cases may rise 92 per cent in US due to climate change*

<sup>6</sup> *Lyme Disease Costs Up to $1.3 Billion Per Year to Treat, Study Finds*

---

| | |
|:---|:---|
| 4 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

The transmission of Lyme disease infection is well understood and documented. Borrelia bacteria colonize in the salivary glands of ticks. When a tick attaches for feeding, it injects its saliva into the human or animal host, bringing along antihistamines, cytokine blockers, anticoagulants and, in the case of an infected tick, Borrelia bacteria.

Early symptoms of Lyme disease (such as a gradually expanding erythematous rash called erythema migrans or more nonspecific symptoms like fatigue, fever, headache, mild stiff neck, arthralgia, or myalgia) can often be overlooked or misdiagnosed as they are often associated with other, often less severe, illnesses. Left untreated, the disease can disseminate and cause more serious complications affecting the joints (arthritis), the heart (carditis) or the nervous system<sup>7</sup>. The medical need for vaccination against Lyme disease is steadily increasing as the geographic footprint of the disease widens<sup>8</sup>.

*VLA15 Vaccine Candidate*

Valneva and its partner, Pfizer, are developing a multivalent protein subunit vaccine candidate that targets the bacteria that cause Lyme disease. VLA15 is designed to prevent Lyme disease by generating antibodies against the outer surface protein A (OspA) on the surface of Borrelia, killing the bacteria before it can be transmitted from the infected tick to the human host. The program was granted Fast Track designation by the FDA in July 2017<sup>9</sup> and, in April 2020, Valneva announced a collaboration with Pfizer for late clinical development and commercialization of VLA15<sup>10</sup>. In June 2022, the terms of this collaboration were updated and Pfizer invested €90.5 ($95) million in Valneva as part of an equity subscription agreement. If VLA15 is approved and commercialized in the United States and Europe, Valneva will be eligible to receive $143 million in milestones from Pfizer, plus ongoing sales royalties ranging from 14% to 22% and an additional $100 million in cumulative sales-based milestones.

Valneva and Pfizer reported results for three Phase 2 clinical trials of VLA15, which together enrolled 1443 healthy participants of 5 to 65 years of age, in which high levels of antibodies against all six serotypes were observed<sup>11,12,13</sup>. These results included the announcement in September 2024 of positive Phase 2 pediatric and adolescent immunogenicity and safety data following vaccination with a second booster dose given one year after receiving the first booster dose. The immune response and safety profile of VLA15 one month after receiving the second booster dose were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season. These latest booster results again demonstrated a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age), adolescent (12 to 17 years of age) and adult

(18 to 65 years of age) participants, measured one month after administration of this second booster dose (month 31). A high proportion of participants seroconverted after the second booster dose, yielding seroconversion rates\* (SCRs) above 90% for all OspA serotypes in all age groups, in-line with SCRs after the first booster. Geometric Mean Titers at one month post first and second booster (i.e. month 19 vs. month 31) were comparably high. The safety and tolerability profile of VLA15 after a second booster dose was comparable to the profile observed after the first booster. To date, no safety concerns have been observed by an independent Data Monitoring Committee (DMC) in any treatment or age group.

Results of Phase 2 trials VLA15-201 and VLA15-202 were published in the peer-reviewed medical journal, the Lancet Infectious Diseases, in June 2024<sup>14</sup>. 18-month Phase 2 booster results were also published in the same journal<sup>15</sup> in July 2024.

In August 2022, the companies initiated a Phase 3 randomized, placebo-controlled clinical study, "Vaccine Against Lyme for Outdoor Recreationists (VALOR)", to investigate the efficacy, safety and immunogenicity of VLA15 in participants five years of age and older in highly endemic regions in the United States, Canada and Europe<sup>16</sup>. The study is designed to follow vaccinated participants over two consecutive tick seasons.

In December 2023, Valneva and Pfizer reported recruitment completion for the study, with the enrollment of 9,437 participants five years of age and older<sup>17</sup>. The companies announced primary vaccination completion in July 2024,<sup>18</sup>.and full vaccination was achieved in August 2025. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.

Pfizer aims to submit a Biologic License Application (BLA) to the FDA and a Marketing Authorization Application (MAA) to the EMA in 2026, subject to positive Phase 3 data.

Shigella Vaccine Candidate – S4V2

*Overview of Shigellosis*

Shigellosis is a global health threat caused by the Gram-negative Shigella bacteria. It is estimated that up to 165 million infections are due to Shigella, of which 62.3 million occur in children younger than five years of age<sup>19</sup>. Diarrheal infection is one of the major causes of morbidity and mortality in numerous countries as well as in travelers and deployed military personnel in endemic regions. There are an estimated 600,000 deaths attributed to Shigella each year and it is the second leading cause for diarrheal deaths<sup>20</sup>. The standard treatment for shigellosis is oral rehydration and antibiotic therapy; however, the bacteria have acquired resistance to many antibiotics, with

<sup>7</sup> *Sykes RA, et al. An estimate of Lyme borreliosis incidence in Western Europe. Journal of Public Health 2017; 39(1): 74-81*

<sup>8</sup> *Center for Disease Control and Prevention. Lyme Disease. Data and Surveillance. April 2021. Available at: https://www.cdc.gov/lyme/datasurveillance/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Flyme%2Fstats%2Findex.html Accessed July 2022.*

<sup>9</sup> *Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15* 

<sup>10</sup> *Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15*

<sup>11</sup> *Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate*

<sup>12</sup> *Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate*

<sup>13</sup> *Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate* 

<sup>14</sup> *https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00175-0/abstract*

<sup>15</sup> *https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00372-4/abstract*

<sup>16</sup> *Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 - Valneva*

<sup>17</sup> *https://valneva.com/press-release/pfizer-and-valneva-complete-recruitment-for-phase-3-valor-trial-for-lyme-disease-vaccine-candidate-vla15/*

<sup>18</sup> *https://valneva.com/press-release/phase-3-valor-lyme-disease-trial-valneva-and-pfizer-announce-primary-vaccination-series-completion/*

<sup>19</sup> *Shigellosis \| CDC Yellow Book 2024*

<sup>20</sup> *Shigellosis \| CDC Yellow Book 2024*

![VAL_Logo_4c.jpg](valn-20250630_g1.jpg)<sub>5</sub>

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

numerous reports of outbreaks of multidrug-resistant strains, making treatment extremely difficult. No approved Shigella vaccine is currently available outside of Russia or China, and the development of Shigella vaccines has been identified as a priority by the World Health Organization (WHO)<sup>21</sup>. The global market for a vaccine against Shigella is estimated to exceed $500 million annually<sup>22</sup>.

*S4V2 Vaccine Candidate*

In August 2024, Valneva entered into an exclusive licensing agreement with LimmaTech Biologics AG for the development, manufacturing and commercialization of Shigella4V (S4V2), the world's most clinically advanced tetravalent vaccine candidate against shigellosis<sup>23</sup>.

At the time the collaboration was established, LimmaTech had already reported positive interim Phase 1/2 data for the S4V2 vaccine candidate<sup>24</sup>, including a favorable safety and tolerability profile as well as robust data on immunogenicity against the four most common pathogenic Shigella serotypes, S. flexneri 2a, 3a, 6, and S. sonnei. The results of the completed Phase 1/2 study confirmed the interim data.

Under the terms of the agreement with Valneva, LimmaTech received an upfront payment of €10 million and will be eligible to receive additional regulatory, development and sales-based milestone payments of up to €40 million as well as low double-digit royalties on sales. LimmaTech is conducting a Phase 2 Controlled Human Infection Model (CHIM) and a Phase 2 pediatric study in Low- and Middle-Income Countries (LMICs). The two clinical trials were initiated in November 2024 and April 2025, respectively. LimmaTech is the regulatory sponsor of the ongoing clinical studies. Upon completion of these studies, Valneva will become the Investigational New Drug (IND) holder and assume all further development, including CMC (chemistry, manufacturing and controls) and regulatory activities, and be responsible for S4V2's commercialization worldwide, if approved.

Zika Vaccine Candidate – VLA1601

*Overview of Zika Virus*

Zika is a mosquito-borne viral disease caused by the Zika virus, a flavivirus transmitted by Aedes mosquitoes<sup>25</sup>. Disease outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and, since 2015, in the Americas. According to the World Health Organization (WHO), there is scientific consensus that Zika is a cause of microcephaly and Guillain-Barré syndrome<sup>26</sup>. Between 2015 and January 2018, over 500,000 cases of suspected Zika infection, as well as many cases of the congenital syndrome associated with Zika, were reported by countries and territories in the Americas, according to the WHO. In addition, the first local mosquito-transmitted Zika virus disease cases were reported in Europe in 2019 and Zika virus outbreak activity was detected in India in 2021.

Zika virus transmission persists in several countries in the Americas and in other endemic regions. To date, a total of

89 countries and territories have reported evidence of mosquito-transmitted Zika virus infection; however, surveillance remains limited globally. There are no preventive vaccines or effective treatments available and, as such, Zika remains a public health threat.

*VLA1601 Vaccine Candidate*

VLA1601 is a highly purified inactivated, adjuvanted vaccine candidate against the Zika virus (ZIKV). It is being developed on the original manufacturing platform of Valneva's licensed Japanese encephalitis vaccine IXIARO, which was further optimized to develop the Company's inactivated, double-adjuvanted COVID-19 vaccine VLA2001, the first COVID-19 vaccine to receive an ordinary marketing authorization in Europe<sup>27</sup>.

Valneva reported positive topline results for VLA1601 from a first-in-human study in November 2018<sup>28</sup>. The incidence of Zika significantly declined after its peak in 2016 due to high population level immunity in affected countries. The Company therefore decided to put this program on hold and prioritized its Lyme disease and chikungunya programs addressing greater health crises.

However, Zika virus transmission persists in several countries in the Americas and in other endemic regions, and Valneva decided to reinitiate clinical development with an optimized vaccine candidate in March 2024<sup>29</sup>. The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is investigating the safety and immunogenicity of VLA1601. Approximately 150 participants, aged 18 to 49 years, in the United States received a low, medium or high dose of VLA1601. In addition, the low dose of VLA1601 has been evaluated with an additional adjuvant. Recruitment and vaccinations have been completed, and results from the trial are expected in the second half of 2025.

The profile of VLA1601 is aligned with the Target Product Profile issued by WHO/UNICEF<sup>30</sup>, which has called for an inactivated whole virus vaccine adjuvanted with alum for a target population of women of reproductive age, which may include pregnant women, and a secondary target population of adolescent and adult males.

The Zika virus disease is on the list of tropical diseases that could qualify for a U.S. FDA Priority Review Voucher<sup>31</sup>.

Pre-clinical Vaccine Candidates

Valneva continues to progress selected pre-clinical assets to further strengthen its future clinical pipeline.

In preclinical R&D, the Company is currently prioritizing VLA2112, a vaccine candidate targeting the Epstein-Barr virus (EBV). EBV is a ubiquitous human pathogen that can cause infectious mononucleosis<sup>32</sup> and is strongly

<sup>21</sup> *Immunization, Vaccines and Biologicals (who.int)*

<sup>22</sup> *Valneva's Initial internal assessment* 

<sup>23</sup>*https://valneva.com/press-release/valneva-and-limmatech-enter-into-a-strategic-partnership-to-accelerate-the-development-of-the-worlds-most-clinically-advanced-tetravalent-shigella-vaccine-candidate/?lang=fr*

<sup>24</sup> *https://lmtbio.com/wp-content/uploads/2024/02/20240221_LimmaTech_Shigella-Interim-Data-PR_Final.pdf*

<sup>25</sup> *https://www.cdc.gov/zika/transmission/index.html*

<sup>26</sup> *http://www.who.int/mediacentre/factsheets/zika/en/*

<sup>27</sup> *Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001 - Valneva*

<sup>28</sup> *Emergent Biosolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus - Valneva*

<sup>29</sup> *https://valneva.com/press-release/valneva-initiates-phase-1-trial-of-second-generation-zika-vaccine-candidate/*

<sup>30</sup> *Target product profile - Zika vaccine.pdf (unicef.org)*

<sup>31</sup> *Tropical Disease Priority Review Voucher Program \| FDA*

<sup>32</sup> *https://www.cdc.gov/epsteinbarr/index.html#:~:text=EBV%20can%20cause%20infectious%20mononucleosis,common%20among%20teens%20and%20adults.*

---

| | |
|:---|:---|
| 6 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

associated with the development of several types of cancer<sup>33</sup> and multiple sclerosis<sup>34</sup>.

Other early-stage activities include vaccine candidates against different enteric diseases.

2.2 Marketed products

Valneva commercializes its three proprietary travel vaccines IXIARO/JESPECT, DUKORAL and IXCHIQ. Sales from these products are complemented by sales from the distribution of third-party products in markets where Valneva operates its own marketing and sales infrastructure (United States, Canada, Nordic countries, United Kingdom, Austria and France).

In June 2025, Valneva announced an exclusive agreement with CSL Seqirus, one of the world's largest influenza vaccine companies, for the marketing and distribution of Valneva's three proprietary vaccines in Germany. Under the agreed terms, CSL Seqirus recently launched Valneva's single-dose chikungunya vaccine IXCHIQ and will begin commercializing Valneva's Japanese encephalitis vaccine IXIARO and cholera/ETEC vaccine DUKORAL from January 2026. This agreement will last for an initial term of three years and includes minimum annual purchasing quantities and standard termination clauses based on change of control and non-performance.

Valneva's sales in the first half of 2025 were €91.0 million compared to €68.3 million in the first half of 2024, which had been impacted by supply constraints. First half 2025 sales included €11.4 million of third party sales. Valneva expects that third-party sales will gradually wind down to less than 5% of its total sales by 2026/2027, allowing the Company to improve gross margins.

Japanese encephalitis vaccine (IXIARO/JESPECT)

IXIARO, or JESPECT in Australia and New Zealand, is a Vero cell culture-derived inactivated Japanese encephalitis vaccine and is the only Japanese encephalitis vaccine currently approved for use in the United States, Canada and Europe. IXIARO is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants aged two months and older, and is a required vaccine for U.S. military personnel who are deployed to areas of risk for Japanese encephalitis. The pediatric indication of IXIARO was granted Orphan Drug designation by the FDA. Japanese encephalitis virus, or JEV, is spread by mosquitos and is the most important cause of viral encephalitis in Asia and the Western Pacific.

Since the approval of IXIARO/JESPECT in 2009, the vaccine label has been extended by the EMA and the FDA for use in children from the age of two months. In addition, an accelerated, alternative vaccination schedule (seven days apart) for adult travelers (18-65 years) was approved by the EMA in 2015 as well as Health Canada and the FDA in 2018.

In March 2020, the FDA approved the extension of IXIARO®'s shelf life from 24 months to 36 months<sup>35</sup>, an

important achievement supporting supply management flexibility.

For the ten years prior to the COVID-19 pandemic, the Company, together with its marketing and distribution partners, successfully increased sales penetration for IXIARO. With the lifting of travel restrictions and continued recovery of the private travel market, that growth has now resumed.

Valneva distributes IXIARO directly to the U.S. Department of Defense (DoD). In January 2025, Valneva secured a new $32.8 million contract with the DoD. Similar to previous DoD contracts, it includes the possibility to purchase additional doses during the twelve months following the signing date.

In the first half of 2025, IXIARO/JESPECT sales increased by 31% to €54.7 million compared to €41.9 million in the first half of 2024. Sales showed double-digit growth to both travelers and the DoD compared to the first half of 2024, when sales were impacted by IXIARO supply constraints.

Cholera / ETEC<sup>36</sup> vaccine (DUKORAL®)

Valneva's cholera vaccine DUKORAL is an oral vaccine indicated for the prevention of diarrhea caused by Vibrio cholera and/or heat labile toxin producing ETEC, the leading cause of travelers' diarrhea. The vaccine contains four inactivated strains of the bacterium Vibrio cholerae serotype O1, and part of a toxin from one of these strains as active substances.

It is authorized for use in the European Union and Australia to protect against cholera, and in Canada, Switzerland, New Zealand and Thailand to protect against cholera and ETEC. DUKORAL is indicated for adults and children from two years of age who will be visiting endemic areas.

Originally licensed in Sweden by SBL Vaccines in 1991, and subsequently in the European Union in 2004, DUKORAL was then prequalified by the WHO. Valneva acquired DUKORAL in 2015 from Janssen Pharmaceuticals as part of the Company's strategic vision to extend its proprietary travel vaccine portfolio.

In the first half of 2025, DUKORAL sales were €17.4 million compared to €14.9 million in the first half of 2024. This 16% growth was notably supported by the supply of doses to the French island of Mayotte for €1.1 million in the first quarter of 2025.

Chikungunya vaccine (IXCHIQ®)

Chikungunya virus (CHIKV) is a mosquito-borne viral disease, causing fever and severe joint pain, which has been identified in over 110 countries in Asia, Africa, Europe and the Americas<sup>37</sup>. The medical and economic burden is expected to grow with climate change and as such, the WHO has highlighted chikungunya as a major public health problem<sup>38</sup>.

IXCHIQ is approved in Europe for the prevention of disease caused by CHIKV in individuals 12 years of age and

<sup>33</sup> *https://www.cancer.org/healthy/cancer-causes/infectious-agents/infections-that-can-lead-to cancer/viruses.html#:~:text=EBV%20infection%20increases%20a%20person's,some%20cases%20of%20stomach%20cancer.*

<sup>34</sup> *https://www.nih.gov/news-events/nih-research-matters/study-suggests-epstein-barr-virus-may-cause-multiple-sclerosis#:~:text=Infection%20with%20Epstein%2DBarr%20virus,could%20help%20prevent%20multiple%20sclerosis*

<sup>35</sup> *Valneva Announces FDA Approval of IXIARO® Shelf Life Extension to 36 Months; New US Military RFP Issued*

<sup>36</sup> *Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium.*

<sup>37</sup> *https://cmr.asm.org/content/31/1/e00104-16*

<sup>38</sup> *Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas (who.int)*

![VAL_Logo_4c.jpg](valn-20250630_g1.jpg)<sub>7</sub>

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

older<sup>39</sup>. It is also approved in the U.S<sup>40</sup>., Canada<sup>41</sup>, United Kingdom and Brazil for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.

Since the start of 2025, Valneva has focused on ramping up sales and launching the vaccine in additional countries, including the Nordics, Austria and Germany. In April 2025, IXCHIQ was granted marketing authorization in Brazil, marking the world's first approval of a chikungunya vaccine in an endemic country. In April 2025, IXCHIQ was also granted label extension in adolescents 12 years of age and older in the European Union, and additional label extension applications are under review in the U.S., Canada, Brazil, and the UK.

In January 2025, Valneva reported further positive Phase 3 data in adolescents for IXCHIQ, which showed a sustained 98.3% seroresponse rate one-year after single vaccination. The one-year data confirmed that a single dose of the vaccine was generally well tolerated in adolescents. Throughout the trial, an independent Data Safety Monitoring Board (DSMB) consistently assessed safety data and found no safety issues.

In the second quarter of 2025, Valneva reported on changes to recommendations for use of IXCHIQ in the U.S., France and Europe based on reports of serious adverse events (SAEs) mainly in elderly people with several underlying medical conditions. As a temporary measure, the FDA, EMA and France's Haute Autorité de Santé suspended the use of the vaccine for individuals in this age group. Both the EMA and FDA announced the lifting of these temporary restrictions in July and August 2025, respectively. The two agencies underlined that IXCHIQ should only be given when there is a significant risk of chikungunya infection and after careful consideration of the benefits and risks. The FDA noted that for most U.S. travelers the risk of exposure to CHIKV is low. Both agencies also reminded healthcare professionals that IXCHIQ is contraindicated in individuals with weakened immune systems due to disease or immunosuppressive treatments, as stated in IXCHIQ's product label in the U.S., Europe and other territories. Additionally, the U.S. Prescribing information (PI) and European Summary of Product Characteristics (SmPC) were updated to reflect the SAE profile observed, especially in people above 65 years of age and older with one or more chronic medical condition.

In the first half of 2025, Valneva recognized IXCHIQ sales of €7.5 million compared to sales of €1.0 million in the first half of 2024, when the vaccine had just been launched in the U.S. IXCHIQ sales in the first half of 2025 benefited from the supply of vaccine doses to the French island of La Réunion in the second quarter of the year as the island experienced a major chikungunya outbreak.

In addition to ramping up sales, Valneva is focused on expanding the vaccine's label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI<sup>42</sup> to support broader access to the vaccine in LMICs, post-marketing trials and potential label extensions in children, adolescents and pregnant women. CEPI will provide Valneva up to $41.3 million of additional funding over five years, with support from the European Union's (EU) Horizon Europe program. Within the framework of this agreement, in December 2024, Valneva announced an exclusive license agreement with the Serum Institute of

India (SII) that will enable supply of the vaccine in Asia. Under the agreement, the Companies will conduct a technology transfer of the current drug product manufacturing process. Valneva will supply its chikungunya vaccine drug substance to SII, which will complete manufacturing and be responsible for seeking and maintaining regulatory approval of the vaccine in India and other countries in Asia. Future commercialization will be based on a profit-sharing model along with single-digit million milestone payments towards technology transfer and regulatory approvals to Valneva. This agreement with SSI complements the agreement Valneva signed with Instituto Butantan, a Brazilian public institute, in 2021 to support broader access to the vaccine in Latin America and in certain low and middle income countries.

Third-party distribution

Valneva distributes certain third-party vaccines in countries where it operates its own marketing and sales infrastructure. In the first half of 2025, third-party sales increased by 9% to €11.4 million compared to €10.5 million in the first half of 2024 as last year's third-party sales were impacted by supply constraints.

The third-party vaccines business supported Valneva's revenues as a complement to its proprietary travel vaccine portfolio, especially during the COVID-19 pandemic. However, the gross margin of third-party sales dilutes Valneva's overall margins, and the Company therefore decided to focus resources on direct sales of its proprietary products. The Company expects third-party sales to gradually wind down to less than 5% of product sales by 2026/2027.

2.3 Other revenues / income

Valneva also derives revenues from collaboration and partnership agreements. The Company's primary source of collaboration revenues is currently through its research collaboration and license agreement with Pfizer Inc., entered into in April 2020<sup>43</sup>, to co-develop and commercialize the Company's Lyme vaccine candidate, VLA15. In June 2020, Pfizer paid Valneva a one-time non-refundable upfront payment of $130 million, plus subsequent development milestone payments totaling $35 million.

Pending approval and commercialization, Pfizer will pay Valneva up to $143 million based on early commercial milestones as well as tiered royalties ranging from 14% to 22%. In addition, Valneva is eligible for up to $100 million in additional milestone payments based on cumulative sales.

Other revenues, including revenues from collaborations, licensing and services, amounted to €6.5 million in the first half of 2025 compared to €2.5 million in the first half of 2024.

Other income amounted to €4.6 million in the first half of 2025 compared to €6.4 million in the first half of 2024. Additionally, a net gain of €90.8 million from the Priority Review Voucher sale was disclosed in the first half of 2024.

2.4 Other Business Updates

<sup>39</sup>*https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/*

<sup>40</sup> *Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva*

<sup>41</sup> *Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ® - Valneva*

<sup>42</sup> *CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine - Valneva*

<sup>43</sup> *Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15 – Valneva*

---

| | |
|:---|:---|
| 8 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Valneva Renewed its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

In March 2025, Valneva announced that it filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) to renew its At-the-Market (ATM) offering facility, which was originally entered into in August 2022.

Pursuant to this financing program, the Company has the option to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0 million of American Depositary Shares (ADS), each ADS representing two of the Company's ordinary shares, from time to time in sales deemed to be an "at the market offering".

The terms and conditions of the new ATM program remain similar to the prior one set up in August 2022. The Sales Agreement will terminate if the maximum program amount is reached or it is terminated early in accordance with its terms.

Since the renewal, Valneva has used its ATM twice with two leading U.S. institutional healthcare specialist investors. In April 2025, it raised $14.3 million of gross proceeds from an ATM transaction with Novo Holdings A/S and in May 2025, it raised $9.0 million of gross proceeds from an ATM transaction with Frazier Life Sciences.

Valneva Appointed Dr. Gerd Zettlmeissl to its Board of Directors

In June 2025, Dr. Gerd Zettlmeissl was appointed to Valneva's Board of Directors for a three-year term.

Dr. Gerd Zettlmeissl is a vaccine expert and biotech entrepreneur with more than 30 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves on the Board of Directors of several non-profit organizations and biotech companies, including Medigene and MinervaX.

Valneva Reappointed James Sulat to its Board of Directors and Announced Departure of Executive Committee Member Franck Grimaud

In June 2025, Valneva reappointed James Sulat to its Board of Directors for a one-year term.

Mr. Sulat is the Vice Chair of the Board of Directors and a member of Valneva's Audit Committee. He is a finance expert and has served notably as CFO of Chiron and CEO of Maxygen.

Valneva also announced that after twenty-six years with Vivalis and Valneva, Mr. Franck Grimaud, Chief Business Officer, and one of Valneva´s co-founders, left the Company on June 25, 2025 to pursue other opportunities.

![VAL_Logo_4c.jpg](valn-20250630_g1.jpg)<sub>9</sub>

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

3 Financial Review

Half Year 2025 Financial Review (Unaudited, consolidated under IFRS)

KEY FINANCIAL INFORMATION

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| Total Revenues | 97562 | 70813 |
| Product Sales | 91020 | 68279 |
| Profit/(loss) for the period | (20818) | 33976 |
| Adjusted EBITDA | (6020) | 56159 |
| Cash and cash equivalents | 161307 | 131413 |

---

Revenues

Valneva's total revenues were €97.6 million in the first half of 2025 compared to €70.8 million in the first half of 2024

Valneva's total product sales reached €91.0 million in the first half of 2025 compared to €68.3 million in the first half of 2024. Foreign currency fluctuations of €0.5 million adversely impacted product sales during the first half of 2025.

Other revenues, including revenues from collaborations, licensing and services increased to €6.5 million in the first half of 2025 compared to €2.5 million in the first half of 2024. The increase was related to revenues recognized under the exclusive license agreement with Serum Institute of India for Valneva's single-shot chikungunya vaccine.

Operating Result and Adjusted EBITDA

Costs of goods and services sold (COGS) were €47.2 million in the first half of 2025. The gross margin on commercial product sales, excluding IXCHIQ®, amounted to 59.2% in the first half of 2025 compared to 47.7% in the first half of 2024. The improvement in gross margin was driven primarily by better manufacturing performance. COGS of €18.9 million related to IXIARO product sales yielded a product gross margin of 65.5% while COGS of €8.2 million related to DUKORAL product sales yielded a product gross margin of 52.9%. Of the remaining COGS in the first half of 2025, €7.0 million related to the third-party products distribution business, €2.5 million to IXCHIQ, €5.9 million to idle capacity costs and €4.6 million to cost of services. In the first half of 2024, overall COGS were €45.6 million, of which €41.1 million related to cost of goods and €4.6 million related to cost of services.

Research and development expenses were €32.4 million in the first half of 2025, compared to €29.7 million in the first half of 2024. This increase was mainly driven by higher costs related to the Shigella vaccine candidate following the R&D collaboration agreement with LimmaTech Biologics AG.

Marketing and distribution expenses in the first half of 2025 were €20.3 million compared to €23.2 million in the first half of 2024. The decrease was mainly related to a planned reduction in advertising, promotional and consultancy spending, which was partly offset by higher costs for warehousing and distribution.

In the first half of 2025, general and administrative expenses were reduced to €19.0 million compared to €22.8 million in the first half of 2024. The reductions were primarily related to lower recruitment spending and insurance charges as well as savings in advisory and professional services.

During the first half of 2024, a net gain of €90.8 million from the sale of the PRV was recorded. The gross proceeds of $103 million were reduced by transaction costs as well as contractual payment obligations related to the sale of the PRV. This one-time net gain did not recur in 2025.

Other income, net of other expenses, decreased to €4.6 million in the first half of 2025 from €6.4 million in the first half of 2024. The reduction was mainly related to lower R&D tax credits during the first half of 2025.

Valneva recorded an operating loss of €16.8 million in the first half of 2025 compared to an operating profit of €46.7 million in the first half of 2024. The decrease was mainly the result of the PRV sale in 2024, partly offset by higher product sales resulting in higher gross profit, as well as reduced SG&A spending in the first half of 2025.

Adjusted EBITDA (as defined below) loss in the first half of 2025 was €6.0 million, whereas in the first half of 2024 an adjusted EBITDA profit of €56.2 million, benefiting from the PRV sale, was recorded.

Net Result

In the first half of 2025, Valneva generated a net loss of €20.8 million. This compared to a net profit of €34.0 million in the first half of 2024, mainly resulting from the sale of the PRV in February 2024.

Finance expense and currency effects in the first half of 2025 resulted in a net finance expense of €2.7 million, compared to a net finance expense of €12.8 million in the first half of 2024. This is mainly related to the development of USD exchange rate versus EUR, which generated a foreign currency profit of €7.8 million in the first half of 2025 compared to a foreign currency loss of €1.7 million in the first half of 2024.

Cash Flow and Liquidity

Net cash used in operating activities amounted to €10.9 million in the first half of 2025 compared to €66.3 million cash used in operating activities in the first half of 2024. The significant reduction in cash used in operating activities compared to last year is driven by the significant increase in sales and efficient cost management.

Cash outflows from investing activities amounted to €1.6 million in the first half of 2025 compared to cash inflows of €87.6 million in the first half of 2024. Cash inflows in the first half 2024 resulted from €90.8 million net proceeds from the sale of the PRV.

Net cash generated from financing activities amounted to €9.3 million in the first half of 2025 compared to a net cash outflow of €16.6 million in the first half of 2024. Cash inflows from the first half of 2025 included €20.1 million net proceeds from two ATM transactions, partly offset by

---

| | |
|:---|:---|
| 10 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

interest payments. Cash outflows for the first half of 2024 mainly consisted of interest and lease payments.

Cash and cash equivalents were €161.3 million as at June 30, 2025, compared to €168.3 million at December 31, 2024.

Management uses and presents IFRS results as well as the non-IFRS measure of Adjusted EBITDA to evaluate and communicate its performance. While non-IFRS measures should not be construed as alternatives to IFRS measures, management believes non-IFRS measures are useful to further understand Valneva's current performance trends, and financial condition.

Adjusted EBITDA is a common supplemental measure of performance used by investors and financial analysts. Management believes this measure provide additional analytical tools. Adjusted EBITDA is defined as net profit /(loss) for the period before income tax, finance income/expense, foreign exchange (gain)/loss, amortization, depreciation, and impairment.

Non-IFRS Financial Measures

A reconciliation of Adjusted EBITDA to net profit / (loss), which is the most directly comparable IFRS measure is set forth in the table below:

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| PROFIT/(LOSS) FOR THE PERIOD | (20818) | 33976 |
| Add: |  |  |
| Income tax (benefits)/expense | 1251 | (158) |
| Financing income | (1065) | (787) |
| Financing expenses | 11585 | 11981 |
| Foreign currency (gain)/loss – net | (7783) | 1652 |
| Amortization | 2439 | 2471 |
| Depreciation | 8371 | 7024 |
| Impairment |  |  |
| ADJUSTED EBITDA | (6020) | 56159 |

---

![VAL_Logo_4c.jpg](valn-20250630_g1.jpg)<sub>11</sub>

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

4 Operational and Strategic Outlook 2025

Valneva's strategy supports its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. This strategy is based on an integrated business model that has allowed the Company to build and advance a portfolio of differentiated clinical and pre-clinical assets as well as grow its commercial business. Valneva is focused on utilizing its proven and validated product development capabilities to rapidly advance solutions addressing unmet needs in infectious diseases towards regulatory approval, with the goal of becoming first-, best- or only-in-class. Valneva has entered into strategic partnerships with other well-established pharmaceutical companies to leverage clinical and commercial capabilities and optimize the potential value of select assets. As Valneva advances its late-stage portfolio, it also remains focused on investing in its research and development pipeline in order to develop its earlier stage assets as well as identify new targets and indications where the Company believes it can make a significant difference.

In the second half of 2025, Valneva will focus on the following goals:

• Continue to progress, together with Pfizer, the VALOR Phase 3 study of Lyme disease vaccine candidate

VLA15 with the objective for Pfizer to submit a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorization Application (MMA) to the EMA in 2026, subject to positive data

• Continue to grow product sales focusing on proprietary products (IXIARO, DUKORAL and IXCHIQ), with the objective to continue building a leading position in the travel vaccines market

• Secure additional label extensions for its chikungunya vaccine IXCHIQ in the U.S., UK and Canada and prepare the launch of Phase 4 post-marketing studies

• Ensure continued progress of the Phase 2 clinical trials for Shigella vaccine candidate S4V2 and continue to advance the Phase 1 study for Zika vaccine candidate VLA1601 and pre-clinical studies for early-stage candidates

• Continue to execute on Valneva's ESG (environmental, social, and governance) strategy and initiatives

---

| | |
|:---|:---|
| 12 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

5 Risk Factors

Valneva considers that the risk factors discussed below are the main risks and uncertainties that the Group may face in the remaining six months of 2025. These risk factors track those in Section 1.5 of the Company's 2024 Universal Registration Document (*Document d'enregistrement universel*, or URD) filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*, or AMF) on March 24, 2025 (AMF number D.25-0140) and in the Company's 2024 annual report on Form 20-F (20-F). These are not the only risks and uncertainties facing the Group in the next six months, and they may also occur in future years. The Company invites investors to review its URD, 20-F and other public disclosure for additional information, including additional risks not discussed below.

Management has established a risk management system in order to monitor and mitigate the risks that are inherent to the Company's industry or associated with its business. However, the Group remains exposed to significant risks, including the following:

Risks relating to the Lyme disease vaccine candidate and the Pfizer Partnership: The Company's strategic partnership with Pfizer to develop and commercialize VLA15 is of critical significance to the Company. Under this agreement, Pfizer has considerable discretion on the development and commercialization of the vaccine candidate, and Pfizer is responsible for the Phase 3 clinical trial and regulatory submission process. Valneva may not agree with or benefit equally from all the decisions taken by Pfizer. If this partnership fails or is terminated for any reason, the Company may not be able to find another partner and will not have sufficient financial resources to pursue the completion of Phase 3 clinical development or commercialization of this vaccine on its own.

First results from the ongoing Phase 3 trial of Valneva's Lyme disease vaccine candidate, VLA15, are expected as soon as all Lyme disease cases are confirmed. The nature of these results will be critical for Valneva's further business evolution. A development failure (including insufficient efficacy or safety) would result in the total loss of the Group's commercial and financial upside expected from Pfizer under the existing agreement. If the Phase 3 results are positive, commercialization of the vaccine candidate will still require regulatory approval and recommendations from local bodies for immunization guidelines, such as the U.S. Centers for Disease Control's Advisory Committee for Immunization Practices (ACIP). Any substantial delays in the data readout or regulatory submissions could have a substantial negative impact on the Group's business.

Risk of Dependence on Sales of Key Products: Valneva's revenues are principally derived from the sales of its three marketed products, IXIARO, DUKORAL and IXCHIQ. Sales of these products are necessarily affected by the strength of the travel industry, the ability of customers to pay for travel vaccines, and the appearance of side effects linked to the products or suspected of being linked to the products. Revenues may be further impacted by other factors, including volatility in the political and economic environment in the markets in which the Group operates and related impacts on consumer behavior, such as discretionary spending on travel. In addition, the Group's product sales may be affected by changes to existing vaccination recommendations or approved indications. For example, due to reports of serious adverse effects (SAEs) in elderly people with co-morbidities, both the EMA and the FDA temporarily paused the use of IXCHIQ for individuals aged 65 and older and 60 and older, respectively, while investigations into the SAEs were

ongoing. While the EMA and FDA have lifted their restrictions, sales of IXCHIQ may still be affected if consumers and health care providers continue to be concerned about potential side effects.

Finally, some of Valneva's vaccines face competition from other vaccines or vaccine candidates for the same indications, which may receive more favorable treatment from regulatory authorities or recommending bodies or may otherwise be preferred by customers.

Product sales also depend on Valneva's ability to manufacture sufficient quantities of its vaccines, and the Group's ability to respond to changes in demand in the short term may be limited. Valneva has experienced supply shortages for both IXIARO and DUKORAL in prior periods.

Geopolitical risks: Volatility in the political environment could have direct or indirect consequences on Valneva's business, including research and development programs, commercial business, financial results or reputation. Legislative changes and disruptions or shifts in priority at governmental agencies or related local bodies could create uncertainty about the timing or outcome of the review of Valneva's product candidates or previously approved products. New operational or policy requirements might be imposed on Valneva as a supplier to government programs, and such programs might be affected by budget cuts. Finally, the imposition of tariffs could lead to rising costs or supply disruptions, which would affect the sales of Valneva's commercial products. As of the date of this report, the 15% tariff on goods imported to the United States from Europe is understood to include pharmaceutical products. Currency fluctuations, particularly involving the US dollar, could also have an impact on Valneva's results of operations.

Risks relating to Financing: Valneva's business is capital-intensive, and it will need to raise additional capital in future periods. Such capital might not be available on acceptable terms or at all, depending on the Group's circumstances and market conditions, which continue to be volatile. Fundraising efforts may divert Valneva's management from their day-to-day activities, which could affect its core business operations. In addition, in 2020, Valneva entered into a debt financing agreement with Deerfield and OrbiMed, under which it is subject to covenants for minimum revenue and liquidity. If the Company is unable to meet these requirements, or if the Company is unable to make required repayments of the debt beginning in 2026, this would result in an event of default and could result in additional costs and disruption, as further described in the Company's annual reports referenced above.

Operational risks: The Group currently depends on its primary manufacturing facilities in Livingston, Scotland, and Solna, Sweden, for the production of IXIARO, DUKORAL and IXCHIQ. If one of these sites were destroyed or seriously damaged by fire or other events, or if a cybersecurity attack resulted in an unexpected suspension of manufacturing, the Group's production would be seriously disrupted or impaired, depending on the nature of the event. In such a situation, the Group would no longer be able to produce the vaccines concerned, in sufficient quantities or at all, and to supply its customers or its clinical trial centers and could therefore suffer considerable losses. The Group could face similar detrimental consequences if the facilities of a key manufacturer were damaged or otherwise affected. Numerous measures have been put in place at Valneva to minimize these risks or their impact, including annual quality and safety audits, business continuity plans, on-site

![VAL_Logo_4c.jpg](valn-20250630_g1.jpg)<sub>13</sub>

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

storage of critical spare parts, and the establishment of safety stocks for materials used in production.

The manufacture of biological materials is delicate and complex, and biological material is very vulnerable to contamination, so industrial yields may vary. The Group may experience delays, manufacturing failures or difficulties in its ability to manufacture its vaccines or in satisfying market demand, particularly if the growth in market demand is faster than the Group's ability to adapt to such demand. Supply shortages may result in penalties from regulatory authorities.

The Group depends upon third-party manufacturers and contractors for the manufacture and supply of its commercial vaccines and product candidates. If such a third party can no longer provide services or failed to meet requirements, Valneva may not be able to supply one or more of its vaccines for several months, and the development and commercialization of the Company's products and product candidates could be limited or delayed.

In addition, the manufacture of biological materials is subject to Good Manufacturing Practices and regular inspections by regulatory authorities. Regulatory authorities update or change their requirements in ways that Valneva is unable to anticipate. Such changes could be costly and could affect the Group's sales and revenue projections. If Valneva or its third-party suppliers fail to comply with Good Manufacturing Practices, Good Distribution Practices or other regulatory requirements or any changes to such requirements, this could result in potential actions against such as the suspension of review of a regulatory submission or the suspension or revocation of manufacturing or distribution authorizations, which could hinder the supply of products by the Group.

Finally, the internal computer and information technology systems of Valneva and its collaborators, service providers and other contractors or consultants are potentially vulnerable to cyber-based attacks and data security breaches, including attacks enhanced or facilitated by artificial intelligence, that may result in damage to or the interruption or impairment of key business processes, or the loss, exposure or corruption of confidential information.

Listed company requirements: As a company listed in France and the United States, Valneva must comply with regulations applicable to listed companies in these jurisdictions. Compliance with existing and anticipated disclosure and other requirements is complex, requires significant time and expense, and may divert the attention of management from other matters, which could negatively impact the Group's business. In particular, the EU Corporate Sustainability Reporting Directive (CSRD) has imposed significant new reporting obligations for Valneva, and disclosure requirements in this area and more generally continue to evolve. In addition, companies that are publicly listed in the United States are subject to a higher risk of shareholder litigation, which could also divert time, attention, and resources away from the Group's business. Failing to comply with applicable U.S. regulations or involvement in lawsuits with U.S. investors could have significant consequences for Valneva and could materially impact the Group's business and results of operations.

Litigation: Risks associated with litigation are set out in Note 19 to the H1 financial statements (Section III of this report).

---

| | |
|:---|:---|
| 14 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

6 Related Parties' Transactions

Bpifrance (Maisons-Alfort - France) is considered as related party due to the number of Valneva shares held and, until June 25, 2025, its representation on the Company's Board of Directors.

In the six months ended June 30, 2025, there was no transaction or change in transactions between related parties which materially affected Valneva's financial position or performance.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 15 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

III. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2025

1 Unaudited Interim Consolidated Statement of Profit or Loss and Comprehensive Income

Unaudited Interim Condensed Consolidated Statement of Profit or Loss

---

| | | | |
|:---|:---|:---|:---|
| | | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | Note | 2025 | 2024 |
| Product sales | *5.5* | 91020 | 68279 |
| Other revenues | *5.5* | 6542 | 2534 |
| REVENUES |  | 97562 | 70813 |
| Cost of goods and services | *5.6* | (47162) | (45628) |
| Research and development expenses | *5.6* | (32441) | (29683) |
| Marketing and distribution expenses | *5.6* | (20310) | (23181) |
| General and administrative expenses | *5.6* | (19034) | (22847) |
| Gain from sale of Priority Review Voucher, net | *5.7* |  | 90833 |
| Other income and expenses, net | *5.7* | 4555 | 6357 |
| OPERATING PROFIT/(LOSS) |  | (16830) | 46663 |
| Finance income | *5.8* | 1065 | 787 |
| Finance expenses | *5.8* | (11585) | (11981) |
| Foreign exchange gain/(loss), net | *5.8* | 7783 | (1652) |
| PROFIT/(LOSS) BEFORE INCOME TAX |  | (19567) | 33818 |
| Income tax benefit/(expense) |  | (1251) | 158 |
| PROFIT/(LOSS) FOR THE PERIOD |  | (20818) | 33976 |
| EARNINGS/(LOSSES) PER SHARE |  |  |  |
| for profit/(loss) for the period attributable to the equity holders of the Company (expressed in € per share) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic |  | (0.13) | 0.25 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted |  | (0.13) | 0.24 |

---

The accompanying Notes form an integral part of these financial statements.

Unaudited Interim Condensed Consolidated Statement of Comprehensive Income

---

| | | | |
|:---|:---|:---|:---|
| | | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | Note | 2025 | 2024 |
| PROFIT/(LOSS) FOR THE PERIOD |  | (20818) | 33976 |
| OTHER COMPREHENSIVE INCOME/(LOSS) |  |  |  |
| Items that may be reclassified to profit or loss |  |  |  |
| Currency translation differences |  | 1402 | (369) |
| Items that will not be reclassified to profit or loss |  |  |  |
| Defined benefit plan actuarial gains/(losses) |  | 24 | (10) |
| Other comprehensive income/(loss) for the period, net of tax |  | 1426 | (379) |
| TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD | TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD | (19391) | 33596 |

---

The accompanying Notes form an integral part of these financial statements.

---

| | |
|:---|:---|
| 16 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

2 Unaudited Interim Condensed Consolidated Statement of Financial Position

---

| | | | |
|:---|:---|:---|:---|
| *in € thousand* | Note | June 30, 2025 | December 31, 2024 |
| ASSETS |  |  |  |
| Non-current assets |  | 187908 | 201020 |
| Intangible assets |  | 23824 | 25258 |
| Right of use assets |  | 18973 | 19232 |
| Property, plant and equipment |  | 128475 | 138883 |
| Deferred tax assets |  | 8009 | 9605 |
| Other non-current assets | *5.12* | 8627 | 8041 |
| Current assets |  | 284717 | 299012 |
| Inventories | *5.10* | 61731 | 53663 |
| Trade receivables | *5.11* | 24122 | 35205 |
| Other current assets | *5.12* | 37557 | 41874 |
| Cash and cash equivalents | *5.13* | 161307 | 168271 |
| TOTAL ASSETS |  | 472625 | 500032 |
| EQUITY |  |  |  |
| Share capital |  | 25528 | 24378 |
| Share premium |  | 666523 | 647600 |
| Other reserves |  | 79126 | 73203 |
| Retained earnings/(Accumulated deficit) |  | (563928) | (551682) |
| Profit/(Loss) for the period |  | (20818) | (12247) |
| TOTAL EQUITY |  | 186432 | 181253 |
| LIABILITIES |  |  |  |
| Non-current liabilities |  | 160534 | 204199 |
| Borrowings | *5.14* | 122362 | 166521 |
| Lease liabilities |  | 25893 | 26432 |
| Refund liabilities | *5.17* | 6587 | 6491 |
| Provisions |  | 1284 | 546 |
| Deferred tax liabilities |  | 4034 | 4162 |
| Other non-current liabilities |  | 373 | 46 |
| Current liabilities |  | 125660 | 114580 |
| Borrowings | *5.14* | 46023 | 20852 |
| Trade payables and accruals | *5.15* | 21116 | 35522 |
| Income tax liability |  | 1598 | 1742 |
| Tax and Employee-related liabilities |  | 18543 | 19458 |
| Lease liabilities |  | 2646 | 2508 |
| Contract liabilities | *5.16* | 520 | 3010 |
| Refund liabilities | *5.17* | 19836 | 19650 |
| Provisions |  | 5850 | 6686 |
| Other current liabilities |  | 9528 | 5152 |
| TOTAL LIABILITIES |  | 286193 | 318779 |
| TOTAL EQUITY AND LIABILITIES |  | 472625 | 500032 |

---

The accompanying Notes form an integral part of these financial statements.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 17 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

3 Unaudited Interim Condensed Consolidated Statement of Cash Flows

---

| | | | |
|:---|:---|:---|:---|
| | | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | Note | 2025 | 2024 |
| CASH FLOWS FROM OPERATING ACTIVITIES |  |  |  |
| Profit/(Loss) for the period |  | (20818) | 33976 |
| Gain from sale of Priority Review Voucher, net |  |  | (90833) |
| Adjustments to reconcile profit/(loss) for the period to cash generated from/(used in) operations | *5.18.1* | 17780 | 23973 |
| Changes in non-current operating assets and liabilities | *5.18.1* | 456 | (1117) |
| Changes in working capital | *5.18.1* | (7788) | (31153) |
| Cash used in operations | *5.18.1* | (10369) | (65154) |
| Income tax paid |  | (575) | (1106) |
| NET CASH GENERATED FROM/(USED IN) OPERATING ACTIVITIES |  | (10943) | (66261) |
| CASH FLOWS FROM INVESTING ACTIVITIES |  |  |  |
| Purchases of property, plant and equipment |  | (2667) | (4104) |
| Proceeds from sale of property, plant and equipment |  | 21 | 172 |
| Purchases of intangible assets |  | (61) | (79) |
| Proceeds from sale of Priority Review Voucher |  |  | 90833 |
| Interest received |  | 1065 | 787 |
| NET CASH GENERATED FROM/(USED IN) INVESTING ACTIVITIES |  | (1642) | 87608 |
| CASH FLOWS FROM FINANCING ACTIVITIES |  |  |  |
| Proceeds/(payments) from issuance of common stock, net of costs of equity transactions |  | 20136 |  |
| Proceeds from borrowings, net of transaction costs | *5.14* |  | (944) |
| Repayment of borrowings | *5.14* |  | (2782) |
| Payment of lease liabilities |  | (1384) | (2136) |
| Interest paid<sup>1</sup> |  | (9452) | (10727) |
| NET CASH GENERATED FROM FROM/(USED IN) FINANCING ACTIVITIES |  | 9299 | (16589) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS |  | (3286) | 4759 |
| Cash and cash equivalents at beginning of the year | *5.13* | 168271 | 126080 |
| Exchange gains/(losses) on cash |  | (3677) | 575 |
| CASH AND CASH EQUIVALENTS AT END OF THE PERIOD |  | 161307 | 131413 |

---

*(1) Cash flows relating to the interest on the lease liabilities amounted to €0.4 million as at June 30, 2025 (June 30, 2024: €0.4 million)* 

The accompanying Notes form an integral part of these financial statements.

---

| | |
|:---|:---|
| 18 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

4 Unaudited Interim Condensed Consolidated Statement of Changes in Equity

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *in € thousand* | Share capital | Share premium | Other reserves | Retained earnings/<br>(Accumulated deficit) | Profit/(loss) <br>for the period | Total<br>equity |
| BALANCE AS AT JANUARY 1, 2025 | 24378 | 647600 | 73203 | (551682) | (12247) | 181253 |
| Total comprehensive income/(loss) |  |  | 1426 |  | (20818) | (19391) |
| Income appropriation |  |  |  | (12247) | 12247 |  |
| Share-based compensation expense: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Value of services |  |  | 4498 |  |  | 4498 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercises |  |  |  |  |  |  |
| Capital Increase | 1150 | 19850 |  |  |  | 21000 |
| Cost of equity transaction, net of tax |  | (928) |  |  |  | (928) |
| BALANCE AS AT JUNE 30, 2025 | 25528 | 666523 | 79126 | (563928) | (20818) | 186432 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *in € thousand* | Share capital | Share premium | Other reserves | Retained earnings/<br>(Accumulated deficit) | Profit/(loss) <br>for the period | Total<br>equity |
| BALANCE AS AT JANUARY 1, 2024 | 20837 | 594003 | 65088 | (450253) | (101429) | 128247 |
| Total comprehensive income/(loss) |  |  | (379) |  | 33976 | 33596 |
| Income appropriation |  |  |  | (101429) | 101429 |  |
| Share-based compensation expense: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Value of services |  |  | 4435 |  |  | 4435 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercises | 55 | (55) |  |  |  |  |
| BALANCE AS AT JUNE 30, 2024 | 20892 | 593948 | 69144 | (551682) | 33976 | 166278 |

---

The accompanying Notes form an integral part of these financial statements.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 19 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

5 Selected Notes to the Unaudited Interim Condensed Consolidated Financial Statements

Note 1 <u>General information</u>

1.1 Corporate Information

Valneva SE (the Company) together with its subsidiaries (the Group or Valneva) is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.

The Company takes a highly specialized and targeted approach, applying deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record of advancing multiple vaccines from early R&D to approval.

Valneva currently markets three proprietary travel vaccines as well as certain third-party vaccines leveraging the Company's established commercial infrastructure. Revenues from the growing commercial business help fuel the continued advancement of the Company's vaccine pipeline. This includes:

&nbsp;&nbsp;&nbsp;&nbsp;• the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer,

&nbsp;&nbsp;&nbsp;&nbsp;• the Company's single-shot vaccine against the chikungunya virus, for which Valneva is continuing to generate additional clinical data to support label extensions,

&nbsp;&nbsp;&nbsp;&nbsp;• the world's most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis,

&nbsp;&nbsp;&nbsp;&nbsp;• an optimized vaccine candidate against the Zika virus

&nbsp;&nbsp;&nbsp;&nbsp;• and pre-clinical vaccine candidates targeting other global public health threats.

As at June 30, 2025, the Group's portfolio includes three commercial vaccines:

&nbsp;&nbsp;&nbsp;&nbsp;▪ IXIARO (also marketed as JESPECT), indicated for the prevention of Japanese encephalitis;

&nbsp;&nbsp;&nbsp;&nbsp;▪ DUKORAL, indicated for the prevention of cholera, and, in some countries, prevention of diarrhea caused by enterotoxigenic Escherichia coli (ETEC); and

&nbsp;&nbsp;&nbsp;&nbsp;▪ IXCHIQ, Valneva's single-shot vaccine indicated for the prevention of disease caused by the Chikungunya virus.

The Company is registered at 6 rue Alain Bombard, 44800 Saint-Herblain, France. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the United States and around 700 employees worldwide.

Valneva SE is a public company listed on Euronext Paris (symbol: VLA) and on the Nasdaq Global Select Market (symbol: VALN).

Significant events of the period and significant agreements

*IXIARO new Supply Contract with the U.S. Government* 

On January 30, 2025 Valneva USA, Inc. signed a new $32.8 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of Valneva's Japanese encephalitis (JE) vaccine, IXIARO. Under this new one year contract, the DoD will buy a minimum of $32.8 million worth of IXIARO vaccines and has the possibility to purchase additional doses during the twelve months following the signing date.

*Valneva Received Marketing Authorization in the UK for its Chikungunya Vaccine, IXCHIQ*

On February 5, 2025 Valneva SE announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for its chikungunya vaccine IXCHIQ. Based on successful Phase 3 data, the single-dose vaccine provides long-lasting protection against chikungunya virus in adults aged 18 and older. This approval marked the fourth regulatory clearance for IXCHIQ.

*Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program*

On March 26, 2025 Valneva SE announced the filing of a prospectus supplement with the U.S. SEC as part of the renewal of its registration statement on Form F-3, related to its existing At-the-Market (ATM) offering program. The ATM Program, originally established in August 2022, allows Valneva to offer and sell up to $75 million in American Depositary Shares (ADS), each representing two ordinary shares. Sales may occur through Jefferies LLC, acting as sales agent, and will be subject to market conditions and regulatory limits. The Company is not obligated to sell any ADS under the program, which retains terms similar to the original 2022 agreement.

The Group issued 4.75 million shares in April 2025 followed by an additional issuance of 2.92 million shares in May 2025 and raised €21.0 million under the ATM program, which was offset by €0.9 million transaction costs. As at June 30, 2025, after the capital increase, the number of shares issued were 170,188,190 compared to 162,521,524 as at December 31, 2024.

*Valneva and LimmaTech Announced First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2*

On April 9, 2025 Valneva SE and LimmaTech Biologics AG announced the vaccination of the first participant in a Phase 2 study evaluating Shigella4V2 (S4V2), the most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis. The trial will assess the

---

| | |
|:---|:---|
| 20 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

safety and immunogenicity of S4V2 in approximately 110 nine-month-old infants in Kenya, aiming to identify the optimal dose for a Phase 3 trial. Shigellosis is a major global health concern, particularly for children under five, and this study, funded by the Gates Foundation, is expected to deliver results in the second half of 2025.

*Valneva Received First Marketing Authorization for IXCHIQ in a Chikungunya Endemic Country*

On April 14, 2025 Valneva SE announced that Brazil's Health Regulatory Agency (ANVISA) granted marketing authorization for IXCHIQ, marking the first approval of a chikungunya vaccine in an endemic country. This also marked a significant step in Valneva's strategy to expand vaccine access, with support from CEPI and the European

Union. IXCHIQ is already approved in several countries, including the U.S., EU, Canada, and the UK, and Valneva is collaborating with Instituto Butantan to ensure access in Latin America.

*Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus*

On June 26, 2025 Valneva Austria GmbH and Valneva Sweden AB entered into exclusive agreements with CSL Seqirus for the marketing and distribution of Valneva's three vaccines in Germany. Starting in July 2025, CSL Seqirus will commercialize Valneva's chikungunya vaccine IXCHIQ, followed by IXIARO and DUKORAL in 2026. This agreement replaces Valneva's previous partnership with Bavarian Nordic and has a term of three years.

1.2 Group information

The following list shows all subsidiaries held by the Company directly or indirectly:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name | Country of incorporation | Consolidation Method | Interest held as at | Interest held as at |
| Name | Country of incorporation | Consolidation Method | June 30, 2025 | December 31, 2024 |
| **Vaccines Holdings Sweden AB** | SE | Full Consolidation | 100% | 100% |
| Valneva Austria GmbH | AT | Full Consolidation | 100% | 100% |
| Valneva Canada Inc. | CA | Full Consolidation | 100% | 100% |
| Valneva France SAS | FR | Full Consolidation | 100% | 100% |
| Valneva Scotland Ltd. | UK | Full Consolidation | 100% | 100% |
| Valneva Sweden AB | SE | Full Consolidation | 100% | 100% |
| Valneva UK Ltd. | UK | Full Consolidation | 100% | 100% |
| Valneva USA, Inc. | US | Full Consolidation | 100% | 100% |
| VBC 3 Errichtungs GmbH | AT | Full Consolidation | 100% | 100% |

---

The closing date for the consolidated financial statements is December 31 of each year.

The Company's site in Saint-Herblain (Nantes, France) includes general and administrative functions as well as research and development facilities. Valneva SE also has a site in Lyon which operates commercial activities.

*Vaccines Holdings Sweden AB* (Solna, Sweden) is the holding company of *Valneva Sweden AB,* also located in Solna, which manufactures DUKORAL and commercializes DUKORAL, IXIARO and IXCHIQ in the Nordic countries.

*Valneva Austria GmbH* (Vienna, Austria) focuses on pre-clinical and clinical development activities of vaccines. The facilities accommodate departments for pre-clinical R&D, technical/clinical product development, quality and regulatory affairs, general and administrative as well as commercial functions. Valneva Austria GmbH commercializes IXIARO, DUKORAL, IXCHIQ and third-party products such as Rabipur/RabAvert and Encepur. Also, Valneva Austria GmbH is involved in external manufacturing steps of IXCHIQ.

*Valneva Canada Inc.*, located in Kirkland, Canada, commercializes IXIARO, DUKORAL, IXCHIQ and third-party products such as KAMRAB.

*Valneva France SAS* (Lyon, France) commercializes IXIARO, DUKORAL, IXCHIQ and third-party products such as Rabipur/RabAvert and Encepur.

*Valneva Scotland Ltd.* (Livingston, Scotland, United Kingdom) is primarily involved in the production of IXIARO and IXCHIQ.

*Valneva UK Ltd.* (Fleet, England, United Kingdom) commercializes DUKORAL, IXIARO and IXCHIQ.

*Valneva USA, Inc.* (Bethesda, Maryland, USA) focuses on the commercialization of IXIARO and IXCHIQ to the U.S. military and the U.S. private market.

*VBC 3 Errichtungs GmbH* (Vienna, Austria), owns the administration and research building used by Valneva Austria GmbH.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 21 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Note 2 <u>Summary of significant accounting policies</u>

The principal accounting policies applied in preparing these interim consolidated financial statements are

outlined below. These policies have been consistently applied to all years presented to date.

2.1&nbsp;&nbsp;&nbsp;&nbsp;Basis of preparation

The unaudited interim condensed consolidated financial statements as at June 30, 2025 and for the six months ended June 30, 2025 and June 30, 2024, have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union (EU) and as issued by the IASB authorizing the presentation of selected explanatory notes.

In consequence, these interim consolidated financial statements must be read in conjunction with the consolidated annual financial statements for the year ended December 31, 2024.

The preparation of financial statements in conformity with IFRS as issued by the IASB and as adopted by the European Union (EU) requires the use of certain critical accounting estimates. It also requires the Group's management to exercise its judgement in applying its accounting policies.

The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements, are disclosed in Note 3.

For ease of presentation, numbers have been rounded and, where indicated, are presented in thousands of Euros. Calculations, however, are based on exact figures. Therefore, the sum of the numbers in a column of a table may not conform to the total figure displayed in the column.

The unaudited interim condensed consolidated financial statements of the Company were approved and authorized for issuance by the Board of Directors after review by the Audit, Compliance and Risk Committee on August 11, 2025.

2.2&nbsp;&nbsp;&nbsp;&nbsp;Impact of new, revised or amended Standards and Interpretations

Standards, amendments to existing standards and interpretations issued by IASB and adopted by the European Union whose application has been mandatory since January 1, 2025

---

| | | | |
|:---|:---|:---|:---|
| New standards, Interpretations and amendments adopted by the Group | New standards, Interpretations and amendments adopted by the Group | Effective date | Effects |
| IAS 21 | Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability | January 1, 2025 |  |
| Editorial Corrections (various) | Periodically issued IASB Editorial Corrections and changes to IFRSs and other pronouncements. | March 31, 2025 |  |

---

The amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect the current or future periods.

Standards, amendments to existing standards and interpretations whose application is not yet mandatory.

The Group did not elect for early application of the following new standards, amendments and interpretations which were issued but not mandatory as at January 1, 2025.

---

| | | | |
|:---|:---|:---|:---|
| New standards, Interpretations and amendments | New standards, Interpretations and amendments | Effective date | Effects |
| IFRS 18 | New standard, IFRS 18 Presentation and Disclosures in Financial Statements | January 1, 2027 | under assessment |
| IFRS 19 | New standard, IFRS 19 Subsidiaries without Public Accountability: Disclosures | January 1, 2027 |  |
| IFRS 7 & IFRS 9 | Amendments IFRS 9 and IFRS 7 regarding the classification and measurement of financial instruments | January 1, 2026 |  |
| Annual improvements to IFRS – Volume 11 | Amendments to IFRS 1 First-time Adoption of International Financial Reporting Standards: Hedge accounting by a first-time adopter | January 1, 2026 |  |
| Annual improvements to IFRS – Volume 11 | Amendments to IFRS 7 Financial Instruments: Disclosures: Gain or loss on derecognition, Disclosure of deferred difference between fair value and transaction price, Introduction and credit risk disclosures | January 1, 2026 |  |
| Annual improvements to IFRS – Volume 11 | Amendments to IFRS 9 Financial Instruments: Lessee derecognition of lease liabilities, Transaction price | January 1, 2026 |  |
| Annual improvements to IFRS – Volume 11 | Amendments to IFRS 10 Consolidated Financial Statements: Determination of a 'de facto agent' | January 1, 2026 |  |
| Annual improvements to IFRS – Volume 11 | Amendments to IAS 7 Statement of Cash Flows: Cost method | January 1, 2026 |  |
| IFRS 7 & IFRS 9 | Amendments IFRS 9 and IFRS 7 regarding the application of the 'own use' exemption to Power Purchase Agreements (PPAs) | January 1, 2026 |  |

---

The Group has not adopted any of the above standards, interpretations or amendments that have been issued, but are not yet effective. Such standards are not currently expected to have a material impact on the Group in the

---

| | |
|:---|:---|
| 22 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

current or future reporting periods and on foreseeable future transactions, except for IFRS 18 for which the

Group is currently assessing the impact in future reporting periods.

Note 3 <u>Critical accounting judgements and key sources of estimation uncertainty</u>

In applying the Group's accounting policies, which are described in Note 2: Summary of significant accounting policies, management is required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognized and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources.

The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the

estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Although it is difficult to predict future liquidity requirements, the Group believes that its existing cash and cash equivalents will be sufficient to fund its operations through at least 12 months after publication of this report.

No additional key sources of estimation uncertainty that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year have been added to those reported as of December 31, 2024.

Note 4 <u>Segment information</u>

The Executive Committee, as the Company's chief operating decision maker (CDM), considers Valneva's operating business in its entirety to allocate resources and assess performance. The Executive Committee evaluates all vaccine candidates and vaccine products together as a

single operating segment, "development and commercialization of prophylactic vaccines". Therefore, the split used to allocate resources and assess performance is based on a functional view, thus correlating to the income statement format.

Note 5 <u>Revenues</u>

Revenues include both revenues from contracts with customers and other revenues (mainly subleases) which are out of scope from IFRS 15:

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| Product sales | 91,020 | 68,279 |
| Other revenues from contracts with customers | 6,152 | 1,847 |
| Other non-IFRS 15 revenue | 389 | 687 |
| REVENUES | 97,562 | 70,813 |

---

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 23 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Disaggregated revenue information

The Group's revenues are disaggregated as follows:

Type of goods or service

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| IXIARO® | 54705 | 41891 |
| DUKORAL® | 17394 | 14945 |
| Third party products | 11418 | 10490 |
| IXCHIQ® | 7504 | 952 |
| **PRODUCT SALES** | 91020 | 68279 |
| Royalties received | 1570 | 1602 |
| Revenues from shipping and handling | 18 | 24 |
| Milestone payment - licenses (1) | 4564 | (123) |
| Other services |  | 343 |
| OTHER REVENUES FROM CONTRACTS WITH CUSTOMERS | 6152 | 1847 |
| Other non-IFRS 15 revenue | 389 | 687 |
| REVENUES | 97562 | 70813 |

---

*(1) Revenues from these products were derived from contractual arrangements and do not represent product sales.*

In the six months ended June 30, 2025 product sales increased by €22.7 million or 33% compared to the same period of 2024 with favorable sales performance recorded for all commercialized products.

IXIARO/JESPECT sales showed a 31% increase in sales, which was the result of sales growing in both Travel and Military channels. The U.S. military returned to a more regular supply pattern, resulting in an increase of sales to the U.S. Department of Defense (DOD) in 2025. In addition higher sales in Europe contributed to the increased sales.

DUKORAL sales in the six months ended June 30, 2025 were 16% higher compared to the same period of 2024. This increase resulted from the supply of doses to the French island of Mayotte and sales growth across most travel markets.

IXCHIQ product sales increased in the six months ended June 30, 2025 by €6.6 million compared to the same

period in 2024 as the vaccine was launched at the end of the first quarter of 2024. Sales in the first half year of 2025 included all doses Valneva supplied to La Réunion, a French overseas region, to respond to the chikungunya outbreak there.

Third Party product sales recorded a 9% increase in the first half of 2025, which was mainly driven by higher sales of Rabipur under the distribution agreement with Bavarian Nordic, following the resolution of external supply constraints impacting sales of the first half year of 2024.

Other revenues, including revenues from collaborations, licensing and services amounted to €6.2 million in the six months ended June 30, 2025 compared to €1.8 million in the six months ended June 30, 2024. The increase in other revenues mainly derives from revenues contracted with the partner for the development of the chikungunya vaccine in India in the first half year of 2025.

---

| | |
|:---|:---|
| 24 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Sales channels for product sales

Products are sold via the following sales channels:

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| Direct product sales | 70,599 | 57,423 |
| Indirect product sales | 20,421 | 10,856 |
| TOTAL PRODUCT SALES | 91,020 | 68,279 |

---

Geographical markets

In presenting information on the basis of geographical markets, revenue is based on the final location where Valneva's distribution partner sells the product or where the customer/partner is located.

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| United States | 23470 | 20137 |
| Germany | 14682 | 7611 |
| Canada | 14464 | 16034 |
| France | 9670 | 2955 |
| Austria | 7064 | 5873 |
| United Kingdom | 6863 | 5554 |
| Nordics | 5892 | 6502 |
| Other Europe | 7015 | 4048 |
| Rest of World | 8442 | 2099 |
| REVENUE TOTAL | 97562 | 70813 |

---

*Nordics includes Finland, Denmark, Norway and Sweden and Rest of World includes India, Israel, Australia, Peru, Japan, Brazil and New Zealand.* 

In the six months ended June 30, 2025, total revenues increased by €26.7 million in comparison to the same period in 2024. Revenues from the United States, Germany and France positively contributed to this result. Sales to the U.S. military organizations increased considerably, being primarily the result of the U.S. military

returning to a more regular supply pattern in 2025. Sales in Germany increased mainly due to higher market demand. In addition, IXCHIQ sales related to the outbreak situation on the French Island La Réunion contributed to the increase in revenues.

Note 6 <u>Expenses by nature</u>

The consolidated income statement line items cost of goods and services, research and development expenses, marketing and distribution expenses and general and administrative expenses include the following items by nature of cost:

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| Consulting and other purchased services | 28620 | 31309 |
| Cost of services and change in inventory | (273) | 4147 |
| Employee benefit expense other than share-based compensation | 44426 | 40956 |
| Share-based compensation expense | 4500 | 3770 |
| Raw materials and consumables used | 7363 | 7802 |
| Depreciation and amortization and impairment | 10811 | 9496 |
| Building and energy costs | 7344 | 6048 |
| Supply, office and IT costs | 4457 | 3694 |
| License fees and royalties | 1877 | 1816 |
| Advertising costs | 5267 | 6979 |
| Warehousing and distribution costs | 2221 | 1743 |
| Travel and transportation costs | 843 | 1847 |
| Other expenses | 1490 | 1733 |
| OPERATING EXPENSES | 118947 | 121339 |

---

The operating expenses in the six months ended June 30, 2025 amounted to €118.9 million, showing a slight decrease compared to the €121.3 million in the six months ended June 30, 2024.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 25 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Expenses for "cost of services and change in inventory" decreased in 2025 by €4.4 million mostly due to improvement in manufacturing performance, and smaller provisions for inventory.

Expenses for "consulting and other purchased services" reduced by €2.7 million in the six months ended June 30, 2025, due to increased in-house recruiting efforts leading to reduced reliance on external agencies. Furthermore, consulting and IT project costs declined due to reduced consultant use. Additionally, renegotiated loan-related insurance premiums contributed further savings.

"Employee benefit expenses other than share-based compensation" increased by €3.5 million in the six months ended June 30, 2025 compared to the six months ended June 30, 2024 because of inflation-related higher salaries and social security contributions. The "share-based compensation expense" showed an increase of €0.7

million from an additional stock option program granted in October 2024.

During the six months ended June 30, 2025, the Group had around 700 employees (Half Year 2024: 695 employees).

"Building and energy costs" increased during the six months ended June 30, 2025, by €1.3 million primarily due to an onerous lease provision and the increased running costs for the new Scottish facility as it is now operational.

The decrease of "advertising costs" by €1.7 million in the six months ended June 30, 2025 compared to the six months ended June 30, 2024 is driven by lower investments following the U.S. launch of IXCHIQ in early 2024.

Note 7 <u>Other income/(expenses), net</u>

Gain from sale of Priority Review Voucher, net

The Company sold the Priority Review Voucher (PRV) received from the FDA for $103 million (€95 million) on February 2, 2024.

The Company was awarded a tropical disease PRV in November 2023 following the FDA's approval of IXCHIQ, Valneva's single-dose, live-attenuated vaccine indicated for the prevention of disease caused by the chikungunya virus. The net gain from the sale of the PRV amounted to €90.8 million. This includes expenses in the amount of €4.2 million which refer to transaction fees as well as to expenses in connection with contractual payment obligations related to the PRV sale.

Remaining other income/(expenses), net

The remaining other income and expenses, net include the following:

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| Research and development tax credit | 2792 | 3610 |
| Grant income | 1951 | 1822 |
| Gain/(loss) on disposal of fixed assets and intangible assets, net | (230) | 48 |
| Gain/(loss) from revaluation of lease agreements |  | 723 |
| Taxes, duties, fees, charges, other than income tax | (215) | (171) |
| Miscellaneous income/(expenses), net | 258 | 324 |
| OTHER INCOME AND EXPENSES, NET | 4555 | 6357 |

---

Other operating income and expenses, net decreased by €1.8 million, or 28%, to €4.6 million for the six months ended June 30, 2025 primarily due to lower research and development tax credit income as well as by the absence of one-off gains from the revaluation of lease agreements recorded in 2024.

The gain from revaluation of lease agreements in 2024 came from the termination of a lease for a warehouse building in Livingston, Scotland, which was no longer in use.

The research and development tax credit in Austria decreased by €0.8 million due to a lower eligible expense base compared to the same period of 2024.

In the six months ended June 30, 2024, the Group recognized grant income from Scottish Enterprise, Scotland's national economic development agency, of €1.8 million, while in the six months ended June 30, 2025, the amount recognized was €0.1 million.

As of June 30, 2025, Valneva had received and recognized €1.8 million (June 30, 2024: €0.0 million) as grant income related to an additional funding from CEPI (Coalition for Epidemic Preparedness Innovations), awarded in the second half of 2024.

---

| | |
|:---|:---|
| 26 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Note 8 <u>Finance income/(expenses), net</u>

Interest income is recognized on a time-proportion basis using the effective interest method.

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| FINANCE INCOME |  |  |
| Interest income from other parties | 1028 | 787 |
| Other financial income | 38 |  |
| TOTAL FINANCE INCOME | 1065 | 787 |
| FINANCE EXPENSES |  |  |
| Interest expense on loans | (11084) | (11296) |
| Interest expense on refund liabilities | (96) | (266) |
| Interest expenses on lease liabilities | (404) | (418) |
| Other interest expense | (1) | (2) |
| TOTAL FINANCE EXPENSES | (11585) | (11981) |
| FOREIGN EXCHANGE GAIN/(LOSSES), NET | 7783 | (1652) |
| FINANCE INCOME/(EXPENSES), NET | (2737) | (12845) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

The interest expense on refund liabilities for the six months ended June 30, 2025 decreased to €0.1 million due to the significant payments made to Pfizer during the first half of 2024. The interest expense on refund liabilities for the six months ended June 30, 2024 was €0.3 million.

The foreign exchange gain in the six months ended June 30, 2025 was primarily driven by non-cash revaluation results of USD denominated liabilities as the USD depreciated against the EUR by 12.81% in 2025. A contrary movement of the USD/EUR rate could be observed in 2024.

Note 9 <u>Impairment testing</u>

At the end of each reporting period Valneva assesses whether there is any indication that an asset may be impaired. Indicators for the necessity of an impairment test are, among others, actual or expected declines in sales or margins and significant changes in the economic environment with an adverse effect on Valneva's business. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less selling costs and value in use.

For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units or CGUs). The cash-generating units correspond with the specific vaccine products and vaccine candidates. Non-financial assets, other than goodwill, that suffered impairment are reviewed for possible reversal of the impairment at each reporting date.

As at June 30, 2025, a triggering event had occurred for IXCHIQ related to the potential label restrictions following the serious adverse events (SAEs) in the French island La

Réunion, therefore the impairment testing procedures were performed. No triggering events were identified for any of the other CGUs.

Impairment testing of the IXCHIQ CGU as at June 30, 2025 did not result in any impairment requirement as the recoverable amount for the CGU was considerably higher than the carrying value of its assets.

As of June 30, 2025 the cumulative impairments amounted to €21.9 million, compared to €22.1 million as of December 31, 2024. The slight decrease related to currency revaluation effects.

The total impairments divide into €4.4 million (December 31, 2024: €4.4 million) for leasehold improvements, €9.5 million (December 31, 2024: €9.7 million) for manufacturing equipment, €3.2 million (December 31, 2024: €3.1 million) for right of use assets, €3.6 million (December 31, 2024: €3.7 million) for acquired R&D costs and €1.2 million (December 31, 2024: €1.2 million) for internal development costs.

Note 10 <u>Inventories</u>

Inventories are stated at the lower of cost and net realizable value. The cost of finished goods and work in progress comprises raw materials, direct labor, other direct costs and related production overheads (based on normal operating capacity) at standard costs. The variances between the actual costs and the standard costs are calculated monthly and allocated to the inventory, so there is no difference between actual and standard costs. Inventories exclude borrowing costs. Provisions for batches which fail to meet quality requirements and may not be sold (failed batches) are deducted from the value of inventories.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 27 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| Raw materials | 27619 | 28086 |
| Work in progress | 49215 | 36832 |
| Finished goods | 18739 | 19493 |
| Purchased goods (third party products) | 2478 | 4762 |
| GROSS AMOUNT OF INVENTORIES BEFORE WRITE-DOWN | 98051 | 89173 |
| Less: write-down provision | (36320) | (35510) |
| INVENTORIES | 61731 | 53663 |

---

As of June 30, 2025 the increase in gross amounts of inventories before write-down is primarily related to the increase in work in progress related to IXCHIQ and DUKORAL, partially offset by the decrease in the purchased goods.

The total write-down provision on inventory amounts to €36.3 million as of June 30, 2025 (December 31, 2024: €35.5 million).

Write-down provisions related to the inventory categories as follows:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| Raw materials | 20,092 | 21,728 |
| Work in progress | 13,538 | 12,600 |
| Finished goods | 2,466 | 591 |
| Purchased goods (third party products) | 224 | 591 |
| TOTAL WRITE-DOWN PROVISION | 36,320 | 35,510 |

---

As at June 30, 2025, €17.2 million in write-down provisions were attributable to raw-material related to the VLA2001 COVID vaccine (unchanged vs. December 31, 2024: €17.2 million).

As at June 30, 2025, the remaining write-down provision in raw materials and work in progress of €16.5 million is based on factors including sales volumes and market demand related to IXIARO, DUKORAL and IXCHIQ vaccines (December 31, 2024: €17.2 million).

As at June 30, 2025 the write down provision for finished goods for IXIARO, DUKORAL and IXCHIQ vaccines based on sales expectations and shelf life of the products amounted to €2.5 million (December 31, 2024: €0.6 million).

The provision for third-party products decreased from €0.6 million at December 31, 2024 to €0.2 million at June 30, 2025.

Note 11 <u>Trade receivables</u>

Trade receivables are initially recognized at fair value. The carrying amount of trade receivables is reduced through an allowance for doubtful accounts. When a trade receivable is considered uncollectible, it is written off against this allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognized in the statement of profit or loss.

Trade receivables include the following:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| Trade receivables | 22297 | 35182 |
| Less: loss allowance of receivables | (52) | (52) |
| Contract assets | 1877 | 75 |
| TRADE RECEIVABLES, NET | 24122 | 35205 |

---

In 2025 and 2024, no material impairment losses were recognized.

As at June 30, 2025 the amount of trade receivables past due (which is defined as being more than 30 days late) reached €0.9 million (December 31, 2024: €2.0 million).

Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value.

As at June 30, 2025 trade receivables included €24.1 million (December 31, 2024: €35.2 million) of receivables from contracts with customers.

Trade receivables decreased by €12.9 million compared to December 31, 2024 primarily due to the timing of sales near period-end and improved cash collections.

As at June 30, 2025 contract assets of €1.9 million (December 31, 2024: €0.1 million) refer to the master collaboration and license agreement with Serum Institute of India (SII) regarding IXCHIQ.

---

| | |
|:---|:---|
| 28 | ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Note 12 <u>Other assets</u>

Other assets include the following:

---

| | | |
|:---|:---|:---|
| | Year ended December 31 | Year ended December 31 |
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| R&D tax credit receivables | 28827 | 31208 |
| Advance payments | 319 | 399 |
| Tax receivables | 3182 | 3686 |
| Prepaid expenses | 7997 | 8878 |
| Contract costs | 3710 | 3710 |
| Consumables and supplies on stock | 782 | 767 |
| Miscellaneous current assets | 57 | 11 |
| OTHER NON-FINANCIAL ASSETS | 44874 | 48659 |
| Deposits | 196 | 198 |
| Miscellaneous financial assets | 1114 | 1058 |
| OTHER FINANCIAL ASSETS | 1310 | 1256 |
| OTHER ASSETS | 46184 | 49915 |
| Less non-current portion | 8627 | 8041 |
| CURRENT PORTION | 37557 | 41874 |

---

Due to the short term nature of the financial instruments included in other assets, their carrying amount is considered to be the same as their fair value.

The line item "R&D tax credit receivables" is mainly related to the received research and development tax

credit primarily in Austria, Scotland and France. The decrease is due to a €5.1 million payment received in March 2025.

The reduction in "tax receivables" is due to the receipt of VAT claims.

Note 13 <u>Cash and cash equivalents</u>

Cash includes cash at bank, cash in hand, and deposits held at call with banks. Cash equivalents include short-term bank deposits and medium-term notes with a maximum maturity of three months that can be assigned or sold on very short notice and are subject to insignificant risk of changes in value in response to fluctuations in interest rates.

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| Cash in hand |  | 1 |
| Cash at bank | 161,307 | 168,269 |
| CASH AND CASH EQUIVALENTS | 161,307 | 168,271 |

---

In 2025, the minimum liquidity requirement for the Group according to the Deerfield & Orbimed Loan Agreement (D&O Loan Agreement) (see Note 14.1) is €35.0 million. Cash at June 30, 2025 includes

€20.1 million of net proceeds from the At The Market (ATM) transactions with leading U.S. institutional healthcare specialist investors Novo Holdings A/S and Frazier Life Science.

Note 14 <u>Borrowings</u>

Borrowings are initially recognized at fair value if determinable, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 29 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Borrowings of the Group at period-end include the following:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| NON-CURRENT | | |
| Debentures and other loans | 122,362 | 166,521 |
| CURRENT | | |
| Debentures and other loans | 46,023 | 20,852 |
| TOTAL BORROWINGS | 168,385 | 187,373 |

---

As of June 30, 2025 the carrying amount of bank borrowings and other loans was €168.4 million. Of this, €162.2 million related to the D&O Loan Agreement.

Other borrowings related to the financing of research and development expenses included the CIR (research and development tax credit in France) of €3.5 million (December 31, 2024: €3.5 million) and the CEPI grant in the amount of €2.6 million (December 31, 2024: €3.0 million), which relates to advance payments that are expected to be paid back in the future.

The maturity of the borrowings is as follows:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| Between 1 and 3 years | 91,425 | 132,489 |
| Between 3 and 5 years | 30,352 | 33,349 |
| Over 5 years | 586 | 683 |
| NON-CURRENT BORROWINGS | 122,362 | 166,521 |
| Current borrowings | 46,023 | 20,852 |
| TOTAL BORROWINGS | 168,385 | 187,373 |

---

The carrying amounts of the Group's borrowings are denominated in the following currencies:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| Borrowings denominated in EUR | 3,539 | 3,540 |
| Borrowings denominated in USD | 164,847 | 183,833 |
| TOTAL BORROWINGS | 168,385 | 187,373 |

---

14.1&nbsp;&nbsp;&nbsp;&nbsp;Other loans

As at June 30, 2025 a total of $200.0 million has been drawn under the D&O Loan Agreement. The book value of the loan amounts to $190.1 million (€162.2 million). Following amendments to the D&O Loan Agreement in March 2024, the interest-only period on the initial $100.0 million (€85.3 million) tranche extends until the first quarter of 2026, and this portion of the loan will mature in the first quarter of 2027. The interest-only period for the tranches drawn in 2023 amounting to $100.0 million extends until the first quarter of 2027, and this portion of the loan will mature in the fourth quarter of 2028. The interest rate on all tranches remains unchanged at 9.95%,

translating into an effective interest rate for the first draw in 2023 of 14.17% and for the second draw in 2023 of 13.47% as of June 30, 2025.

The loan is secured by substantially all of Valneva's assets, including its intellectual property, and is guaranteed by Valneva SE and certain of its subsidiaries. The minimum liquidity requirement is €35.0 million for 2025. The twelve-month rolling minimum revenue requirement of €115.0 million is effective for 2025. The Group does not expect these limitations to affect its ability to meet its cash obligations.

The D&O Loan Agreement is included in the balance sheet item "Borrowings" and developed as follows:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| BALANCE AS AT JANUARY 1 | 180841 | 167520 |
| Transaction costs |  | (944) |
| Accrued interest | 10926 | 22530 |
| Payment of interest | (8974) | (18978) |
| Exchange rate difference | (20592) | 10713 |
| BALANCE AS AT CLOSING DATE | 162202 | 180841 |
| Less: non-current portion | (117609) | (161420) |
| CURRENT PORTION | 44593 | 19421 |

---

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 30 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

14.2&nbsp;&nbsp;&nbsp;&nbsp;Fair value of borrowings and other loans

The fair value of the borrowings and other loans are calculated by discounting the contractual cash flows with interest rates derived from relevant bond yields and swap rates and adjusted for any further potential risk and liquidity risks related to the nature of each loan. The

relevant bond yields were determined by an internal analysis based on Moody's RiskCalc corporate rating methodology. In the six months ended June 30, 2025, the resulting calculations revealed no material difference between the carrying amount and the fair value.

Note 15 <u>Trade payables and accruals</u>

Trade payables and accruals include the following:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| Trade payables | 5,682 | 12,639 |
| Accrued expenses | 15,433 | 22,883 |
| TOTAL | 21,116 | 35,522 |
| Less non-current portion |  |  |
| CURRENT PORTION | 21,116 | 35,522 |

---

The carrying amounts of trade and other payables are considered to be the same as their fair values, due to their short-term nature. All trade payables and accruals are current.

Note 16 <u>Contract liabilities</u>

A contract liability has to be recognized when the customer already provided the consideration or part of the consideration before an entity has fulfilled its performance obligation (agreed goods or services which should be delivered or provided) resulting from the "contract".

Development of contract liabilities is presented in the table below:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| BALANCE AS AT JANUARY 1 | 3010 | 5697 |
| Revenue recognition | (3220) | (462) |
| Redemption |  | (4777) |
| Addition | 720 | 2500 |
| Exchange rate differences | 10 | 53 |
| BALANCE AS AT CLOSING DATE | 520 | 3010 |
| Less non-current portion |  |  |
| CURRENT PORTION | 520 | 3010 |

---

As at June 30, 2025, €0.4 million of the total €0.5 million related to upfront payments for analytical support and drug substance manufacturing on ongoing contracts.

In the six months ended June 30, 2025, revenue of €2.5 million was recognized in connection with the license and technology transfer performance obligation under the master collaboration and license agreement with Serum Institute of India (SII) regarding IXCHIQ.

In the year ended December 31, 2024, the redemption in the amount of €4.8 million relates to a U.S. Military distribution agreement for which the obligation to replace vaccine doses was fulfilled in 2024. An upfront payment of €2.5 million is shown under additions and refers to the master collaboration and license agreement with Serum Institute of India (SII) regarding IXCHIQ.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 31 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Note 17 <u>Refund liabilities</u>

A refund liability has to be recognized when the customer already provided a consideration which is expected to be refunded partially or totally. It is measured at the amount the Company has an obligation to repay or amounts which did not meet the criteria for revenue recognition in the past, but there are no remaining goods and services to be provided in the future.

Development of refund liabilities during the period is presented below:

---

| | | |
|:---|:---|:---|
| *in € thousand* | June 30, 2025 | December 31, 2024 |
| BALANCE AS AT JANUARY 1 | 26141 | 39941 |
| Additions | 4023 | 4013 |
| Other releases | (1505) | (19901) |
| Interest expense capitalized | 96 | 360 |
| Exchange rate difference | (2332) | 1728 |
| **BALANCE AS AT CLOSING DATE** | 26423 | **26141** |
| Less non-current portion | (6587) | (6491) |
| CURRENT PORTION | 19836 | 19650 |

---

As at June 30, 2025, out of the total of €26.4 million, an amount of €18.4 million - all current - (December 31, 2024: €18.6 million) is connected to the Collaboration and License Agreement with Pfizer. In the first half of 2025 additions of €2.1 million were made in connection with the Pfizer Collaboration and License Agreement (December 31, 2024: €2.6 million).

Refund liabilities of €6.6 million (of which €6.6 million is non-current) (December 31, 2024 €6.5 million of which €6.5 million was non-current) relate to the expected payment to GlaxoSmithKline (GSK) due to the termination of the strategic alliance agreements (SAA) in 2019.

The remaining amount of €1.4 million out of the total of €26.4 million relates to refund liabilities mainly due to statistical return provision and rebates as at June 30, 2025 (December 31, 2024: €1.1 million).

In the period ended June 30, 2025 other releases primarily related to reversal of statistical return provision and rebate accruals while in the period ended December 31, 2024 it related largely to payments made in connection with the terms of the Pfizer Collaboration and License Agreement.

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 32 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Note 18 <u>Cash flow information</u>

Cash generated/(used) in operations

The following table shows the adjustments to reconcile profit/(loss) to cash generated/(used) from operations:

---

| | | |
|:---|:---|:---|
| | Six months ended June 30, | Six months ended June 30, |
| *in € thousand* | 2025 | 2024 |
| PROFIT/(LOSS) FOR THE PERIOD | (20818) | 33976 |
| Gain from sale of Priority Review Voucher, net |  | (90833) |
| Adjustments to reconcile profit/(loss) for the period to cash generated from/(used in) operations: |  |  |
| Depreciation and amortization | 10811 | 9496 |
| Share-based compensation expense | 4500 | 3770 |
| Income tax expense/(income) | 1251 | (158) |
| (Profit)/loss from disposal of property, plant, equipment and intangible assets | 230 | (48) |
| (Profit)/loss from disposal of financial assets | **(38)** | **—** |
| Provision for employer contribution costs on share-based compensation plans | 113 | (1442) |
| Other non-cash (income)/expense | (9645) | 1161 |
| Interest income | (1028) | (787) |
| Interest expense | 11585 | 11981 |
| Total adjustments to reconcile profit/(loss) for the period to cash generated from/(used in) operations | 17780 | 23973 |
| CHANGES IN NON-CURRENT OPERATING ASSETS AND LIABILITIES (EXCLUDING THE EFFECTS OF ACQUISITION AND CONSOLIDATION): |  |  |
| Other non-current assets | (591) | (558) |
| Long term refund liabilities | 96 | 93 |
| Other non-current liabilities and provisions | 951 | (652) |
| TOTAL CHANGES IN NON-CURRENT OPERATING ASSETS AND LIABILITIES | 456 | (1117) |
| CHANGES IN WORKING CAPITAL (EXCLUDING THE EFFECTS OF ACQUISITION AND EXCHANGE RATE DIFFERENCES ON CONSOLIDATION): |  |  |
| Inventory | (10491) | (3331) |
| Trade and other receivables | 13978 | 3745 |
| Contract liabilities | (2500) | (560) |
| Refund liabilities | 155 | (16749) |
| Trade and other payables and provisions | (8930) | (14258) |
| Total changes in working capital | (7788) | (31153) |
| CASH GENERATED/(USED) IN OPERATIONS | (10369) | (65154) |

---

Note 19 <u>Contingencies and litigations</u>

Following the merger of Vivalis SA and Intercell AG in 2013, former Intercell shareholders challenged the cash compensation and the share exchange ratio in court.

A court-appointed expert largely upheld the original exchange ratio but recommended higher cash compensation with final opinions issued through April 2023.Nonetheless, the final outcome will depend on the court's position on specific legal points and the Court has not made a decision yet. The Company therefore assessed the probability of several scenarios and decided to hold a provision of €5.2 million to cover the reassessed risk and potential legal costs (December 31, 2024: €5.2 million).

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 33 |

---

------

---

| |
|:---|
| **Unaudited interim condensed consolidated financial statements as at June 30, 2025** |
| Valneva SE |

---

Note 20 <u>Related-party transactions</u>

In the six months ended June 30, 2025, there have been some changes to related parties specifically in the key management personnel.

Bpifrance (Maisons-Alfort - France) continues to be considered as a related party due to its significant influence through material transactions and through a membership in the Company's Board of Directors until June 25, 2025.

Rendering of services

Transactions with related parties are carried out on arm's length terms and were not material during the six months ended June 30, 2025.

Valneva has borrowed amounts amounting to 80% of French Tax Authorities receivables relating to Research

Tax Credits for 2021, 2022 and 2023 from Bpifrance. The total amount borrowed from Bpifrance is €3.5 million on which Valneva pays interest.

No material transactions were carried out during the period with Bpifrance (Maisons-Alfort - France).

Key management compensation

In the six months ended June 30, 2025, the aggregate compensation of key management amounted to €4.2 million (in the six months ended June 30, 2024: €3.5 million) and represents mostly salaries and share based payment expenses.

Note 21 <u>Events after the reporting period</u>

Subsequent to the reporting date and up to the date of authorization for the issuance of the financial statements, no events have occurred that require adjustment to, or disclosure in, the financial statements

---

| | |
|:---|:---|
| ![VAL_Logo_4c.jpg](valn-20250630_g1.jpg) | 34 |

---

------

**A EUROPEAN COMPANY (SOCIETAS EUROPAEA) WITH A BOARD OF DIRECTORS** 

Registered Office;

6 rue Alain Bombard, 44800 Saint-Herblain (France)

Nantes Trade and Companies Registry (R.C.S.)

No. 422 497 560

## Exhibit 99.1

**VALNEVA SE**

Campus Bio-Ouest \| 6, Rue Alain Bombard

44800 Saint-Herblain, *France*

**Valneva Reports Half Year 2025 Financial Results and**

**Provides Corporate Updates**

• **Total revenues of €97.6 million compared to €70.8 million in the first half of 2024**

• **Cash and cash equivalents of €161.3 million at end of June 2025**

• **Further clinical and regulatory progress**

• **2025 financial outlook confirmed** 

**Saint-Herblain (France), August 12, 2025** – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year, ended June 30, 2025, and confirmed its 2025 financial guidance. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company's website (Financial Reports – Valneva).

Valneva will provide a live webcast of its first half 2025 results conference call beginning <br>at 3 p.m. CEST/9 a.m. EDT today. This webcast will also be available on the Company's website. Please refer to this link: https://edge.media-server.com/mmc/p/kkyrijxj

**First Half 2025 Financial Update**

• Total revenues were €97.6 million compared to €70.8 million for the first half of 2024, an increase of 37.8%

• Product sales reached €91.0 million compared to €68.3 million in the first half of 2024, an increase of 33.3%

• Net loss of €20.8 million compared to a net profit of €34.0 million in the first half of 2024, which included one-time net proceeds of €90.8 million from the sale of a Priority Review Voucher (PRV)<sup>1</sup>

• Significant reduction in operating cash burn (€10.9 million in the first half of 2025 compared to €66.3 million in the first half of 2024)

• Cash and cash equivalents were €161.3 million as at June 30, 2025, compared to <br>€168.3 million as at December 31, 2024

oCash at June 30, 2025 included €20.1 million of net proceeds from two At The Market (ATM) transactions with leading U.S. institutional healthcare investors Novo Holdings A/S and Frazier Life Sciences in Q2 2025<sup>2</sup>

**Financial Outlook**

<sup>1</sup> *<u>Valneva Announces Sale of Priority Review Voucher for $103 Million - Valneva</u>*

<sup>2</sup> *https://valneva.com/investors/regulated-information/*

August 12, 2025 VALNEVA SE

------

The Company confirms the following guidance for fiscal year 2025:

• Product sales expected to grow to €170-180 million, driving positive cash flow for the commercial business

• Total revenues expected to reach €180-190 million

• Total R&D investments expected between €90-100 million, partially offset by grant funding and anticipated R&D tax credits

• Continued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; targeting more than 50% lower operating cash burn compared to the prior year

**Peter Bühler, Valneva's Chief Financial Officer**, commented, "As we approach the potentially transformative Phase 3 data readout for our Lyme disease vaccine candidate, we remain strategically focused on two key objectives - growing our commercial sales and effectively managing our cash. In the first half of the year, we again delivered double-digit sales growth while continuing to expand access to our vaccines. We also substantially reduced our spending and successfully leveraged our ATM program to welcome two new leading healthcare investors among our main shareholders, strengthening our financial position ahead of this important clinical catalyst."

**Key R&D, Regulatory, and Commercial Updates**

• Finalized new $32.8 million IXIARO<sup>®</sup> supply contract with the U.S. Department of Defense (DoD) in January 2025<sup>3</sup>

• Signed exclusive agreement with CSL Seqirus to market and distribute Valneva's three proprietary vaccines in Germany <sup>4</sup>

• VALOR Lyme disease study on track; Pfizer confirmed all vaccinations have been completed<sup>5</sup>

• Responded to French government's call for vaccine supply of IXCHIQ<sup>®</sup> to combat chikungunya outbreak in La Réunion<sup>6</sup>

• Announced European Medicines Agency (EMA) and Food and Drug Administration (FDA)'s decisions to lift temporary restrictions on use of IXCHIQ<sup>®</sup> in elderly following their thorough review of the vaccine on reported serious adverse events (SAE's) in that age group

• Secured additional marketing authorizations for IXCHIQ<sup>®</sup> in the United Kingdom (UK) and Brazil<sup>7</sup>, marking the world's first approval of a chikungunya vaccine in an endemic country<sup>8</sup>

• Received label extension for IXCHIQ<sup>®</sup> in Europe for individuals 12 years of age and older<sup>9</sup> and submitted additional adolescent label extension applications in other countries

<sup>3</sup> *Valneva Announces New IXIARO*<sup>®</sup> *Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Valneva*

<sup>4</sup> *Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - Valneva*

<sup>5</sup> *https://s206.q4cdn.com/795948973/files/doc_financials/2025/q2/PFE-USQ_Transcript_2025-08-05.pdf*

<sup>6</sup> *Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion - Valneva*

<sup>7</sup> *Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ® - Valneva*

<sup>8</sup> *Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country - Valneva*

<sup>9</sup> *Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above - Valneva*

&nbsp;&nbsp;&nbsp;&nbsp;

------

• Reported positive Phase 2 six-month antibody persistence and safety results in children<sup>10</sup> vaccinated with IXCHIQ<sup>®</sup>, as well as high sustained immune response in adolescents one year after a single vaccination<sup>11</sup>

• Announced first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2<sup>12</sup>

**Financial Information**

(Unaudited results, consolidated per IFRS)

---

| | | |
|:---|:---|:---|
| **€ in million** | **6 months ended June 30,** | **6 months ended June 30,** |
|  | **2025** | **2024** |
| Total revenues | 97.6 | 70.8 |
| Product sales  | 91.0 | 68.3 |
| Net profit / (loss) | (20.8) | 34.0 |
| Adjusted EBITDA<sup>13</sup> | &nbsp;&nbsp;&nbsp;&nbsp;(6.0) | 56.2 |
| Cash | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 161.3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 131.4 |

---

**Commercial Portfolio**

Valneva's commercial portfolio is composed of three travel vaccines, IXIARO<sup>®</sup>/JESPECT<sup>®</sup>, DUKORAL<sup>®</sup> and IXCHIQ<sup>®</sup>. The Company also distributes certain third-party products in countries where it operates its own marketing and sales infrastructure.

Valneva's sales in the first half of 2025 were €91.0 million compared to €68.3 million in the first half of 2024, which had been impacted by supply constraints. First half 2025 sales included €11.4 million of third-party sales. Valneva expects that third-party sales will gradually wind down to less than 5% of its total sales by 2026/2027, allowing the Company to improve gross margins.

In June 2025, Valneva announced an exclusive agreement with CSL Seqirus<sup>14</sup>, one of the world's largest influenza vaccine companies, for the marketing and distribution of Valneva's three proprietary vaccines in Germany. Under the agreed terms, CSL Seqirus recently launched Valneva's single-dose chikungunya vaccine IXCHIQ<sup>®</sup> and will begin commercializing Valneva's Japanese encephalitis vaccine IXIARO<sup>®</sup> and cholera/ETEC vaccine DUKORAL<sup>®</sup> from January

<sup>10</sup> *Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - Valneva*

<sup>11</sup> *Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - Valneva*

<sup>12</sup> *Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 - Valneva*

<sup>13</sup> *For additional information on Adjusted EBITDA, please refer to the "Non-IFRS Financial Measures" section at the end of the PR*

<sup>14</sup> *Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - Valneva*

&nbsp;&nbsp;&nbsp;&nbsp;

------

2026. This agreement has an initial three-year term and includes minimum annual purchasing quantities and standard termination clauses based on change of control and non-performance.

**JAPANESE ENCEPHALITIS VACCINE IXIARO**<sup>®</sup>**/JESPECT**<sup>®</sup>

In the first half of 2025, IXIARO<sup>®</sup>/JESPECT<sup>®</sup> sales increased by 30.6% to €54.7 million compared to €41.9 million in the first half of 2024. Sales to both travelers and the DoD showed double-digit growth compared to the first half of 2024, when sales were impacted by IXIARO<sup>®</sup> supply constraints.

In January 2025, Valneva secured a new $32.8 million contract with the DoD<sup>15</sup>. Similar to previous DoD contracts, it includes the possibility to purchase additional doses during the twelve months following the signing date.

**CHOLERA / ETEC**<sup>16</sup>**-DIARRHEA VACCINE DUKORAL**<sup>®</sup>

In the first half of 2025, DUKORAL<sup>®</sup> sales were €17.4 million compared to €14.9 million in the first half of 2024. This 16.4% growth was notably supported by the supply of doses to combat an outbreak on the French island of Mayotte for €1.1 million in the first quarter of 2025.

**CHIKUNGUNYA VACCINE IXCHIQ**<sup>®</sup>

In the first half of 2025, Valneva reported IXCHIQ<sup>®</sup> sales of €7.5 million compared to sales of €1.0 million in the first half of 2024, when the vaccine had just been launched in the U.S. First half IXCHIQ<sup>®</sup> sales benefited from the supply of vaccine doses to the French island La Réunion, primarily in the second quarter of the year, as the island experienced a major chikungunya outbreak.

In addition to ramping up sales and launching the vaccine in additional countries, Valneva is focused on expanding the vaccine's label and access. In April 2025, IXCHIQ<sup>®</sup> was granted marketing authorization in Brazil, marking the world's first approval of a chikungunya vaccine in an endemic country. In April 2025, IXCHIQ<sup>®</sup> was also granted label extension in adolescents 12 years of age and older in the European Union, and additional label extension applications are under review in the U.S., Canada, Brazil, and the UK.

In the second quarter of 2025, Valneva reported changes to recommendations for use of IXCHIQ<sup>®</sup> in the U.S., France and Europe based on reports of serious adverse events (SAEs) mainly in elderly people with several underlying medical conditions. As a temporary measure, the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and France's Haute Autorité de Santé suspended the use of the vaccine for individuals in this age group. Both the EMA and

<sup>15</sup> *Valneva Announces New IXIARO*<sup>®</sup> *Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Valneva*

<sup>16</sup> *Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium.*

&nbsp;&nbsp;&nbsp;&nbsp;

------

FDA announced the lifting of these temporary restrictions in July<sup>17</sup> and August<sup>18</sup> 2025, respectively. The two agencies underlined that IXCHIQ<sup>®</sup> should only be given when there is a significant risk of chikungunya infection and after careful consideration of the benefits and risks. The FDA noted that for most U.S. travelers the risk of exposure to CHIKV is low. Both agencies also reminded healthcare professionals that IXCHIQ<sup>®</sup> is contraindicated in individuals with a weakened immune system due to disease or immunosuppressive treatments, as stated in IXCHIQ<sup>®</sup>'s product label in the U.S., Europe and other territories. Additionally, the U.S. Prescribing information (PI) and European Summary of Product Characteristics (SmPC) were updated to reflect the SAE profile observed, especially in people above 65 years of age and older with one or more chronic medical condition.

**Clinical Vaccine Candidates** 

**LYME DISEASE VACCINE CANDIDATE – VLA15** 

**Phase 3 vaccination completed** 

Valneva and Pfizer are developing VLA15, a Phase 3 vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common serotypes found in the United States and Europe. VLA15 is the only Lyme disease program in late-stage clinical development today and has received Fast Track designation from the FDA.

Pfizer is currently executing the randomized, placebo-controlled Phase 3 field efficacy study, VALOR (Vaccine Against Lyme for Outdoor Recreationists). Phase 3 vaccinations have now been completed.

Participants will be monitored for the occurrence of Lyme disease cases until the end of the 2025 Lyme disease season (end of October), with topline data expected as soon as all Lyme disease cases are confirmed.

Pfizer aims to submit a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorization Application (MAA) to EMA in 2026, subject to positive Phase 3 data. If VLA15 is approved and commercialized in the United States and Europe, Valneva will be eligible to receive $143 million in milestones from Pfizer, plus ongoing sales royalties ranging from 14% to 22% and an additional $100 million in cumulative sales-based milestones.

**SHIGELLA VACCINE CANDIDATE – S4V2**

**Two Phase 2 trials ongoing**

S4V2 is the world's most clinically advanced tetravalent vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria, under development in collaboration with LimmaTech Biologics AG.

<sup>17</sup> *Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted \| European Medicines Agency (EMA)*

<sup>18</sup> *https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-update-safety-ixchiq-chikungunya-vaccine-live*

&nbsp;&nbsp;&nbsp;&nbsp;

------

Shigellosis is the second leading cause of fatal diarrhea worldwide. It is estimated that up to 165 million cases of disease and an estimated 600,000 deaths are attributed to Shigella each year<sup>19</sup>, particularly among children in Low Middle-Income Countries.

In April 2025, Valneva and LimmaTech announced vaccination of the first participant in a Phase 2 infant safety and immunogenicity study of S4V2. This followed the launch of a Phase 2b Human Challenge Study (CHIM) in the United States<sup>20</sup>, sponsored and conducted by LimmaTech. Results for the infant and CHIM studies are expected in the second half of 2025 and first half of 2026, respectively. Subject to positive results for both Phase 2 studies, Valneva will assume responsibility for all further development<sup>21</sup>.

No approved multivalent Shigella vaccine is currently available outside of Russia or China, and the development of Shigella vaccines has been identified as a priority by the World Health Organization (WHO)<sup>22</sup>. In October 2024, the U.S. FDA granted Fast Track designation to S4V2, recognizing its potential to address a serious condition and fill an unmet medical need<sup>23</sup>. The global market for a vaccine against Shigella is estimated to exceed $500 million annually<sup>24</sup>.

**ZIKA VACCINE CANDIDATE – VLA1601**

**Phase 1 ongoing with optimized vaccine candidate**

VLA1601 is a novel adjuvanted inactivated vaccine candidate against the mosquito-borne disease caused by the Zika virus (ZIKV). In March 2024, Valneva initiated a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA1601<sup>25</sup>. Sentinel recruitment and vaccinations have been completed and results from the trial are expected this year.

Zika virus transmission persists in several countries in the Americas and in other endemic regions, such as India and Africa. To date, a total of 89 countries and territories have reported evidence of mosquito transmitted Zika virus infection<sup>26</sup>; however, surveillance remains limited globally.

There are no preventive vaccines or effective treatments available and, as such, Zika remains a public health threat and is included in the FDA's Tropical Disease Priority Review Voucher Program<sup>27</sup>.

**First Half 2025 Financial Review** 

(Unaudited, consolidated under IFRS)

<sup>19</sup> *<u>Shigellosis \| CDC Yellow Book 2024</u>*

<sup>20</sup> *Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2*

<sup>21</sup> *Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate - Valneva*

<sup>22</sup> *<u>Immunization, Vaccines and Biologicals (who.int)</u>*

<sup>23</sup> *<u>Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V - Valneva</u>*

<sup>24</sup> *LEK analysis*

<sup>25</sup> *<u>Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - Valneva</u>*

<sup>26</sup> *<u>Zika virus disease (who.int)</u>*

<sup>27</sup> *<u>Tropical Disease Priority Review Voucher Program \| FDA</u>*

&nbsp;&nbsp;&nbsp;&nbsp;

------

**Revenues**

Valneva's total revenues were €97.6 million in the first half of 2025 compared to €70.8 million in the first half of 2024.

Valneva's total product sales reached €91.0 million in the first half of 2025 compared to €68.3 million in the first half of 2024. Foreign currency fluctuations of €0.5 million adversely impacted product sales during the first half of 2025.

Other revenues, including revenues from collaborations, licensing and services increased to €6.5 million in the first half of 2025, compared to €2.5 million in the first half of 2024. The increase was related to revenues recognized under the exclusive license agreement with the Serum Institute of India for Valneva's single-shot chikungunya vaccine.

**Operating Result and adjusted EBITDA** 

Costs of goods and services sold (COGS) were €47.2 million in the first half of 2025. The gross margin on commercial product sales, excluding IXCHIQ<sup>®</sup>, amounted to 59.2% in the first half of 2025 compared to 47.7% in the first half of 2024. The improvement in gross margin was driven primarily by better manufacturing performance.

COGS of €18.9 million related to IXIARO<sup>®</sup> product sales yielded a product gross margin of 65.5%, while COGS of €8.2 million related to DUKORAL<sup>®</sup> product sales yielded a product gross margin of 52.9%. Of the remaining COGS in the first half of 2025, €7.0 million related to the third-party products distribution business, €2.5 million to IXCHIQ<sup>®</sup>, €5.9 million to idle capacity costs and €4.6 million to cost of services. In the first half of 2024, overall COGS were €45.6 million, of which €41.1 million related to cost of goods and €4.6 million related to cost of services.

Research and development expenses were €32.4 million in the first half of 2025, compared to €29.7 million in the first half of 2024. This increase was mainly driven by higher costs related to the Shigella vaccine candidate following the R&D collaboration agreement with LimmaTech Biologics AG.

Marketing and distribution expenses in the first half of 2025 were €20.3 million compared to €23.2 million in the first half of 2024. The decrease was mainly related to a planned reduction in advertising, promotional and consultancy spending, which was partly offset by higher costs for warehousing and distribution.

In the first half of 2025, general and administrative expenses were reduced to €19.0 million compared to €22.8 million in the first half of 2024. The reductions were primarily related to lower recruitment spending and insurance charges as well as savings in advisory and professional services.

&nbsp;&nbsp;&nbsp;&nbsp;

------

During the first half of 2024, a net gain of €90.8 million from the sale of the PRV was recorded. The gross proceeds of $103 million were reduced by transaction costs as well as contractual payment obligations related to the sale of the PRV. This one-time net gain did not recur in 2025.

Other income, net of other expenses decreased to €4.6 million in the first half of 2025, from €6.4 million in the first half of 2024. The reduction was mainly related to lower R&D tax credits during the first half of 2025.

Valneva recorded an operating loss of €16.8 million in the first half of 2025 compared to an operating profit of €46.7 million in the first half of 2024. The decrease was mainly the result of the PRV sale in 2024, partly offset by higher product sales resulting in higher gross profit, as well as reduced SG&A spending in the first half of 2025.

Adjusted EBITDA (as defined below) loss in the first half of 2025 was €6.0 million, whereas in the first half of 2024, an adjusted EBITDA profit of €56.2 million, benefiting from the PRV sale, was recorded.

**Net Result** 

In the first half of 2025, Valneva generated a net loss of €20.8 million. This compared to a net profit of €34.0 million in the first half of 2024, mainly resulting from the sale of the PRV in February 2024.

Finance expense and currency effects in the first half of 2025 resulted in a net finance expense of €2.7 million, compared to a net finance expense of €12.8 million in the first half of 2024. This is mainly related to the development of USD exchange rate versus EUR, which generated a foreign currency profit of €7.8 million in the first half of 2025 compared to a foreign currency loss of €1.7 million in the first half of 2024.

**Cash Flow and Liquidity** 

Net cash used in operating activities amounted to €10.9 million in the first half of 2025 compared to €66.3 million cash used in operating activities in the first half of 2024. The significant reduction in cash used in operating activities compared to last year is driven by the significant increase in sales and efficient cost management.

Cash outflows from investing activities amounted to €1.6 million in the first half of 2025 compared to cash inflows of €87.6 million in the first half of 2024. Cash inflows in the first half of 2024 resulted from €90.8 million net proceeds from the sale of the PRV.

Net cash generated from financing activities amounted to €9.3 million in the first half of 2025 compared to a net cash outflow of €16.6 million in the first half of 2024. Cash inflows from the first half of 2025 included €20.1 million net proceeds from two ATM transactions partly offset by interest payments. Cash outflows for the first half of 2024 mainly consisted of interest and lease payments.

&nbsp;&nbsp;&nbsp;&nbsp;

------

Cash and cash equivalents were €161.3 million as at June 30, 2025, compared to €168.3 million at December 31, 2024.

**Non-IFRS Financial Measures**

Management uses and presents IFRS results as well as the non-IFRS measure of Adjusted EBITDA to evaluate and communicate its performance. While non-IFRS measures should not be construed as alternatives to IFRS measures, management believes non-IFRS measures are useful to further understand Valneva's current performance, performance trends, and financial condition.

Adjusted EBITDA is a common supplemental measure of performance used by investors and financial analysts. Management believes this measure provides additional analytical tools. Adjusted EBITDA is defined as net profit / (loss) for the period before income tax, finance income/expense, foreign exchange (gain)/loss, amortization, depreciation, and impairment.

A reconciliation of Adjusted EBITDA to operating loss, which is the most directly comparable IFRS measure, is set forth below:

---

| | | |
|:---|:---|:---|
| **€ in million** | **6 months ended June 30** | **6 months ended June 30** |
| (unaudited results, consolidated per IFRS) | **2025** | **2024** |
| Net profit/(loss) | (20.8) | 34.0 |
| Add:  |  |  |
| Income tax benefit/expense | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.3 | &nbsp;&nbsp;&nbsp;&nbsp;(0.2) |
| Total Finance income | (1.1) | (0.8) |
| Total Finance expense | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12.0 |
| Foreign exchange (gain)/loss – net | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (7.8) | 1.7 |
| Amortization | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5 |
| Depreciation | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.4 | 7.0 |
| Impairment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - |
| **Adjusted EBITDA** | **(6.0)** | &nbsp;&nbsp;&nbsp;&nbsp;**56.2** |

---

**About Valneva SE**

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.

&nbsp;&nbsp;&nbsp;&nbsp;

------

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at www.valneva.com<u>.</u>

---

| | |
|:---|:---|
| <br>**Valneva Investor and Media Contacts**<br>Laetitia Bachelot-Fontaine<br>VP, Global Communications and European Investor Relations<br>M +33 (0)6 4516 7099<br>Laetitia.bachelotfontaine@valneva.com | <br>Joshua Drumm, Ph.D.<br>VP, Global Investor Relations <br>M +001 917 815 4520<br>joshua.drumm@valneva.com |

---

**Forward-Looking Statements**

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships, clinical trials, technology transfer, regulatory approvals, product indications, sales and spending. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays (including in connection with changes in leadership at the national or agency level), reports of adverse events following vaccination with a Valneva product, competition in general, currency fluctuations, the impact of global economic and political events, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;